[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1570
1. Restuccia DF, Hemmings BA: From man to mouse and back again: advances in defining tumor AKTivities in vivo. Dis Model Mech; 2010 Nov-Dec;3(11-12):705-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From man to mouse and back again: advances in defining tumor AKTivities in vivo.
  • Mouse tumor models that replicate AKT activation typical of human cancers provide a powerful means by which to investigate mechanisms of oncogenic signaling, identify potential therapeutic targets and determine treatment regimes with maximal therapeutic efficacy.
  • This Perspective highlights recent advances using in vivo studies that reveal how AKT signaling supports tumor formation, cooperates with other mutations to promote tumor progression and facilitates tumor-cell dissemination, focusing on well-characterized prostate carcinoma mouse models that are highly sensitive to AKT activation.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20940316.001).
  • [ISSN] 1754-8411
  • [Journal-full-title] Disease models & mechanisms
  • [ISO-abbreviation] Dis Model Mech
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


2. Bernstein RM, Cozen H: Evaluation of back pain in children and adolescents. Am Fam Physician; 2007 Dec 1;76(11):1669-76
MedlinePlus Health Information. consumer health - Back Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of back pain in children and adolescents.
  • Back pain is fairly prevalent in healthy children and adolescents.
  • When children or adolescents seek medical care for back pain, it is highly likely that underlying pathology will be identified.
  • Common causes of back pain include nonspecific pain or muscle strain, herniated disk, spondylolysis, scoliosis, and Scheuermann's kyphosis.
  • Less common causes include tumor, infection, and sickle cell crisis.
  • If nonspecific back pain is suspected, treatment may include home-based exercise, physical therapy, or nonsteroidal anti-inflammatory drugs.
  • [MeSH-major] Back Pain / etiology
  • [MeSH-minor] Acute Disease. Adolescent. Algorithms. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Blood Cell Count. Blood Sedimentation. C-Reactive Protein / metabolism. Child. Chronic Disease. Diagnosis, Differential. Exercise Therapy. Humans. Scoliosis / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18092709.001).
  • [ISSN] 0002-838X
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 9007-41-4 / C-Reactive Protein
  • [Number-of-references] 41
  •  go-up   go-down


3. Kim DH, Choi KH, Cho YD: Clear cell sarcoma of the upper thoracic back muscle. J Korean Neurosurg Soc; 2009 Feb;45(2):112-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell sarcoma of the upper thoracic back muscle.
  • Clear cell sarcoma (CCS), also called malignant melanoma of soft parts, is a rare malignant soft tissue tumor and is often associated with tendons or aponeuroses.
  • Most of CCS involve extremities, especially lower extremities, but a tumor occurring in the trunk is rare.
  • We report an extremely rare case of CCS originated in the upper thoracic back muscle.
  • To our knowledge, this case is the second report of CCS of the back muscle.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg Oncol. 2006;4:48 [16893467.001]
  • [Cites] Skeletal Radiol. 2000 Apr;29(4):187-95 [10855466.001]
  • [Cites] Arch Pathol Lab Med. 2006 Mar;130(3):343-8 [16519562.001]
  • [Cites] Skeletal Radiol. 2005 Sep;34(9):543-6 [16132975.001]
  • [Cites] Skeletal Radiol. 2005 Mar;34(3):167-70 [15592669.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):969-75 [10491522.001]
  • [Cites] Skeletal Radiol. 1999 Apr;28(4):240-3 [10384998.001]
  • [Cites] Am J Surg Pathol. 1992 Dec;16(12):1197-204 [1463095.001]
  • [Cites] Am J Surg Pathol. 1983 Jul;7(5):405-13 [6614306.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Feb;149(1):63-7 [15104285.001]
  • [Cites] Cytojournal. 2007;4:15 [17631685.001]
  • [Cites] Singapore Med J. 2007 Jul;48(7):e203-5 [17609816.001]
  • [Cites] J Surg Oncol. 2007 May 1;95(6):519-22 [17192915.001]
  • [Cites] Can J Surg. 2007 Feb;50(1):58-9 [17391618.001]
  • [Cites] Arch Pathol Lab Med. 2007 Jan;131(1):152-6 [17227118.001]
  • [Cites] J Orthop Sci. 2004;9(2):171-4 [15045547.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Sep;145(2):121-5 [12935923.001]
  • [Cites] Can Assoc Radiol J. 2002 Oct;53(4):237-40 [12391930.001]
  • [Cites] Pediatr Blood Cancer. 2006 May 1;46(5):659 [16261586.001]
  • (PMID = 19274123.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2651559
  • [Keywords] NOTNLM ; Back muscle / Clear cell sarcoma
  •  go-up   go-down


Advertisement
4. Wang H, Ahrens C, Rief W, Gantz S, Schiltenwolf M, Richter W: Influence of depression symptoms on serum tumor necrosis factor-α of patients with chronic low back pain. Arthritis Res Ther; 2010;12(5):R186
MedlinePlus Health Information. consumer health - Depression.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of depression symptoms on serum tumor necrosis factor-α of patients with chronic low back pain.
  • INTRODUCTION: Patients with chronic low back pain (cLBP) have high rates of comorbid psychiatric disorders, mainly depression.
  • Our previous work showed a higher serum level of an inflammatory marker tumour necrosis factor-alpha (TNFα) in patients with cLBP, which did not correlate with intensity of low back pain alone.
  • In the present study we investigated the cross-sectional associations of depressive symptoms, low back pain and their interaction with circulating levels of TNFα.
  • All subjects underwent a blood draw for the assessment of serum TNFα and completed a standardised questionnaire regarding medication, depression scores according to the German version of Centre for Epidemiological Studies Depression Scale (CES-D), pain intensity from a visual analogue scale, and back function using the Roland and Morris questionnaire.
  • The pain intensity reported by both patient groups was similar, while the patients with depression had higher CES-D scores (P < 0.001) and worse back function (P < 0.001).
  • [MeSH-major] Depression / blood. Depression / epidemiology. Low Back Pain / blood. Low Back Pain / epidemiology. Tumor Necrosis Factor-alpha / blood

  • Genetic Alliance. consumer health - Depression.
  • Genetic Alliance. consumer health - Dysthmia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Psychopharmacology (Berl). 2003 Dec;170(4):429-33 [12955291.001]
  • [Cites] Z Orthop Ihre Grenzgeb. 2004 Mar-Apr;142(2):146-52 [15106058.001]
  • [Cites] Psychol Bull. 2004 Jul;130(4):601-30 [15250815.001]
  • [Cites] Pain. 2004 Aug;110(3):578-87 [15288398.001]
  • [Cites] Spine (Phila Pa 1976). 1983 Mar;8(2):141-4 [6222486.001]
  • [Cites] J Affect Disord. 2006 Nov;96(1-2):107-10 [16782205.001]
  • [Cites] Brain Behav Immun. 2007 Jan;21(1):47-59 [16647243.001]
  • [Cites] Brain Behav Immun. 2007 Jan;21(1):9-19 [17070667.001]
  • [Cites] Brain Behav Immun. 2007 Feb;21(2):153-60 [17088043.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Feb;320(2):507-15 [17068203.001]
  • [Cites] Indian J Physiol Pharmacol. 2007 Jan-Mar;51(1):69-75 [17877295.001]
  • [Cites] Pain. 2007 Nov;132(1-2):195-205 [17890011.001]
  • [Cites] Z Rheumatol. 2007 Oct;66(6):473-83 [17849126.001]
  • [Cites] Clin J Pain. 2008 Mar-Apr;24(3):273-8 [18287835.001]
  • [Cites] Int J Geriatr Psychiatry. 2008 Apr;23(4):347-55 [17979214.001]
  • [Cites] J Rheumatol. 2008 Jul;35(7):1366-70 [18528959.001]
  • [Cites] Psychosom Med. 2008 Oct;70(8):890-7 [18799425.001]
  • [Cites] Gen Hosp Psychiatry. 2009 Mar-Apr;31(2):116-22 [19269531.001]
  • [Cites] Front Biosci (Landmark Ed). 2009;14:5031-51 [19482603.001]
  • [Cites] Psychiatry Clin Neurosci. 2007 Aug;61(4):415-20 [17610667.001]
  • [Cites] Pain. 2000 Mar;85(1-2):145-51 [10692613.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2000 Apr;278(4):R947-55 [10749783.001]
  • [Cites] Br J Pharmacol. 1992 Nov;107(3):660-4 [1472964.001]
  • [Cites] Psychol Med. 1992 Nov;22(4):1045-50 [1488477.001]
  • [Cites] Psychol Bull. 1993 May;113(3):472-86 [8316610.001]
  • [Cites] Psychosom Med. 1993 Jul-Aug;55(4):364-79 [8416086.001]
  • [Cites] Brain Res. 1993 Oct 1;623(2):321-4 [8221116.001]
  • [Cites] Ann N Y Acad Sci. 1995 Jul 21;762:474-6 [7668562.001]
  • [Cites] Pol J Pharmacol. 1996 Sep-Oct;48(5):503-6 [9112692.001]
  • [Cites] Percept Mot Skills. 1997 Dec;85(3 Pt 2):1163-7 [9450266.001]
  • [Cites] Br J Psychiatry. 1997 Nov;171:444-8 [9463603.001]
  • [Cites] Exp Neurol. 1998 May;151(1):138-42 [9582261.001]
  • [Cites] Adv Exp Med Biol. 1999;461:317-29 [10442180.001]
  • [Cites] Mol Psychiatry. 1999 Jul;4(4):328-32 [10483048.001]
  • [Cites] Ann Rheum Dis. 1957 Dec;16(4):494-502 [13498604.001]
  • [Cites] Brain Behav Immun. 2005 Jan;19(1):3-11 [15581732.001]
  • [Cites] Expert Opin Pharmacother. 2005 Mar;6(3):369-76 [15794728.001]
  • [Cites] Clin Rheumatol. 2004 Dec;23(6):566; author reply 567 [15801083.001]
  • [Cites] Behav Brain Res. 2005 May 7;160(1):125-34 [15836907.001]
  • [Cites] Eur J Pain. 2005 Aug;9(4):463-84 [15979027.001]
  • [Cites] Arch Gen Psychiatry. 2005 Dec;62(12):1377-84 [16330726.001]
  • [Cites] Trends Immunol. 2006 Jan;27(1):24-31 [16316783.001]
  • [Cites] Annu Rev Psychol. 2000;51:29-57 [10751964.001]
  • [Cites] Exp Neurol. 2001 Jun;169(2):386-91 [11358451.001]
  • [Cites] J Peripher Nerv Syst. 2001 Jun;6(2):67-72 [11446385.001]
  • [Cites] Rheumatology (Oxford). 2001 Jul;40(7):743-9 [11477278.001]
  • [Cites] Disabil Rehabil. 2002 Apr 15;24(6):334-40 [12017467.001]
  • [Cites] J Neurosci. 2002 Sep 1;22(17):7809-17 [12196604.001]
  • [Cites] Manag Care. 2002 Aug;11(8 Suppl):7-10; discussion 21-5 [12233202.001]
  • [Cites] Pain. 2002 Sep;99(1-2):313-21 [12237210.001]
  • [Cites] Inflamm Res. 2007 Jan;56(1):32-7 [17334668.001]
  • [Cites] Curr Pain Headache Rep. 2007 Apr;11(2):98-103 [17367587.001]
  • [Cites] Schizophr Res. 2007 May;92(1-3):207-10 [17337162.001]
  • [Cites] Brain Behav Immun. 2007 Jul;21(5):553-60 [17204395.001]
  • [Cites] Neurology. 2007 Jul 3;69(1):42-9 [17606879.001]
  • [Cites] Keio J Med. 2007 Jun;56(2):48-52 [17609588.001]
  • [Cites] Brain Behav Immun. 2002 Oct;16(5):513-24 [12401465.001]
  • [Cites] Brain Behav Immun. 2002 Oct;16(5):544-56 [12401468.001]
  • [Cites] Int J Neuropsychopharmacol. 2002 Dec;5(4):357-73 [12466035.001]
  • [Cites] Brain Behav Immun. 2002 Dec;16(6):675-84 [12480498.001]
  • [Cites] Brain. 2003 Feb;126(Pt 2):438-50 [12538410.001]
  • [Cites] Eur J Neurosci. 2003 Feb;17(4):791-804 [12603269.001]
  • [Cites] Brain Behav Immun. 2003 Feb;17 Suppl 1:S112-8 [12615196.001]
  • [Cites] Brain Behav Immun. 2003 Apr;17(2):86-93 [12676571.001]
  • [Cites] J Neurosci. 2003 Apr 1;23(7):2517-21 [12684435.001]
  • [Cites] Ann Med. 2003;35(1):2-11 [12693607.001]
  • [Cites] Neurosci Lett. 2003 Aug 28;347(3):179-82 [12875915.001]
  • [Cites] Biol Psychiatry. 2003 Aug 1;54(3):283-94 [12893104.001]
  • [Cites] Arch Gen Psychiatry. 2003 Oct;60(10):1009-14 [14557146.001]
  • (PMID = 20937109.001).
  • [ISSN] 1478-6362
  • [Journal-full-title] Arthritis research & therapy
  • [ISO-abbreviation] Arthritis Res. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ PMC2991021
  •  go-up   go-down


5. Arican O, Ciralik H, Sasmaz S: Multiple plaques on the back: S-100 negative benign granular cell tumor. J Dermatol; 2005 Jul;32(7):585-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple plaques on the back: S-100 negative benign granular cell tumor.
  • Granular cell tumor is a rarely seen disease characterized by a gradually developing nodular lesion, which is difficult to diagnose.
  • The tumor usually appears in the 4th-6th decades of life, more frequently in women and blacks, and has a multifocal location in 10-25% of the cases.
  • The present paper describes an 18-year-old female patient with benign granular cell tumor.
  • This rarely seen type of tumor was S-100 negative and has been detected in biopsies taken from multiple asymptomatic plaques and maculopapular lesions.
  • They were 0.5-4 cm in diameter, light brown in color, and with clear contours and had been gradually growing on her back the last nine years.
  • [MeSH-major] Granular Cell Tumor / pathology. S100 Proteins / analysis. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Back. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16335876.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / S100 Proteins
  •  go-up   go-down


6. Kiyohara T, Kumakiri M, Kuwahara H, Saitoh A, Ansai S: Rippled-pattern sebaceoma: a report of a lesion on the back with a review of the literature. Am J Dermatopathol; 2006 Oct;28(5):446-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rippled-pattern sebaceoma: a report of a lesion on the back with a review of the literature.
  • A 68-year-old Japanese man presented with a nodule that had been present for 5 to 6 years on the right side of the back.
  • Microscopic examination revealed a bulb-like tumor in the dermis, contiguous with the overlying epidermis.
  • The tumor revealed characteristics of rippled-pattern sebaceoma.
  • The present case is the first reported rippled-pattern sebaceous neoplasm on the back.
  • Many spindle cell tumors, such as basal cell carcinoma, pleomorphic adenoma, dermatofibrosarcoma protuberans, myofibroblastoma, and leiomyoblastoma, in addition to trichoblastoma and sebaceoma, can have a rippled-pattern.
  • [MeSH-major] Back. Hair Follicle / pathology. Neoplasms, Basal Cell / pathology. Sebaceous Gland Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Follow-Up Studies. Humans. Immunohistochemistry. Keratins / analysis. Male. Neoplasm Proteins / analysis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17012924.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  • [Number-of-references] 23
  •  go-up   go-down


7. Camarero-Mulas C, Andrés García-Marín A, Sánchez-Rodríguez T, Vaquero-Rodríguez A, Fábregues-Olea A, Pino-Jiménez A, Turégano-Fuentes F: [Low back pain as a manifestation of an intra-abdominal desmoplastic small round cell tumor]. Rev Gastroenterol Mex; 2010;75(3):353-6
Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Low back pain as a manifestation of an intra-abdominal desmoplastic small round cell tumor].
  • [Transliterated title] Dolor lumbar como manifestación de un tumor intra-abdominal desmoplásico de células pequeñas y redondas.
  • The desmoplastic small round cell tumor is infrequent.That mainly affects male youngsters and is normally located at the abdomino-pelvic cavity, being its clinic unspecific.
  • The diagnosis is confirmed by the presence of a specific chromosomal translocation: t (11; 22), (p13; q12).
  • [MeSH-major] Desmoplastic Small Round Cell Tumor / complications. Gastrointestinal Neoplasms / complications. Low Back Pain / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20959191.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


8. Bilginer B, Söylemezoğlu F, Cila A, Akalan N: Intraventricular dysembryoplastic neuroepithelial tumor-like neoplasm with disseminated spinal tumor. Turk Neurosurg; 2009 Jan;19(1):69-72
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraventricular dysembryoplastic neuroepithelial tumor-like neoplasm with disseminated spinal tumor.
  • Dysembryoplastic neuroepithelial tumor (DNT)- like lesions arise in extracortical locations and behave in a benign fashion similar to that of cortical DNTs.
  • Here we report a case of 9-year-old boy with a complaint of headache and back pain.
  • A third ventricular mass lesion with disseminated spinal tumor was detected on his magnetic resonance imaging.
  • The presence of floating neurons in a mucinous matrix, oligodendrocyte-like cells (OLCs) aligning axonal columns and vessels, immunohistochemical profile of the neoplasm in addition to the clinical and radiological manifestations of the patient led to the diagnosis of "DNT-like neoplasm of the third ventricle".

  • Genetic Alliance. consumer health - Dysembryoplastic Neuroepithelial Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19263357.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


9. Lee IJ, Yoo YM, Lim H, Park MC: Glomus tumor of the back: a rare location. J Craniofac Surg; 2009 Nov;20(6):2153-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glomus tumor of the back: a rare location.
  • A 44-year-old man presented with a 5-year history of localized pain on his back, and a 1.5-cm round, touch-induced painful mass was palpated.
  • A subsequent diagnostic evaluation revealed the presence of a glomus tumor.
  • Glomus tumors are rare, benign, small vascular tumors, which originate from glomus bodies present in the reticular dermis.
  • Glomus tumors constitute less than 2.0% of all primary soft tissue tumors, approximately 80% of the lesions are located in the upper extremity, and more than 75% are subungually located.
  • Nevertheless, to the best of our knowledge, this glomus tumor that occurred on the back is very rare.
  • [MeSH-major] Back / pathology. Glomus Tumor / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19884843.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Kajihara M, Sugawara Y, Sakayama K, Abe Y, Miki H, Mochizuki T: Subcutaneous fibrolipoma in the back. Radiat Med; 2006 Aug;24(7):520-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous fibrolipoma in the back.
  • A 65-year-old man presented with a subcutaneous giant mass in his upper back.
  • The tumor had a massive fatty and non-adipose component that enhanced heterogeneously on contrast-enhanced computed tomography and magnetic resonance imaging.
  • After surgery, the tumor was histologically diagnosed as a fibrolipoma.
  • Subcutaneous fibrolipoma is a rare neoplasm that is defined as a subtype of lipoma.
  • [MeSH-major] Lipoma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Aged. Back. Humans. Male. Subcutaneous Tissue

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17058147.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Tejera-Vaquerizo A, Herrera-Ceballos E, Bosch-García R, Fernandez-Orland A, Matilla A: Composite cutaneous hemangioendothelioma on the back. Am J Dermatopathol; 2008 Jun;30(3):262-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite cutaneous hemangioendothelioma on the back.
  • We report a new case of this rare tumor located on the back of a 23-year-old woman.
  • This neoplasm is considered to be of borderline or low-grade malignancy, because despite its frequency it rarely metastasizes.
  • [MeSH-minor] Adult. Antigens, CD31 / analysis. Back. Biomarkers, Tumor / analysis. Epithelioid Cells / chemistry. Epithelioid Cells / pathology. Female. Humans. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18496428.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Biomarkers, Tumor
  •  go-up   go-down


12. Kumar S, Deepak P, Acharya A: Hsp70 induces Th1 polarization through tumor-associated macrophages in a T-cell lymphoma. Neoplasma; 2007;54(2):113-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hsp70 induces Th1 polarization through tumor-associated macrophages in a T-cell lymphoma.
  • Tumor progression produces immunoregulatory phenotype of macrophages in tumor bearing host (TBH), that mediate immunosuppression through increased production of soluble factors.
  • Here, we reported that in vitro treatment of TAMs with autologous Hsp70 purified from DL-bearing mice reverse back the tumor induced macrophage suppressor activity, suggesting that Hsp70 can restore TAMs production of Th1-polarizing cytokines.
  • LPS stimulation failed to overcome tumor-induced dysregulation of IL-1, IL-12, IL-15 and IFN-gamma production.
  • Summarizing, these data demonstrates that Hsp70 restore Th1 polarizing cytokines production in the TBH and thus ascribe a possibility to develop a novel immunotherapeutic regime by using TAMs that could contribute well to the correction of tumor induced immune dysfunction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17319783.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Cytokines; 0 / HSP70 Heat-Shock Proteins
  •  go-up   go-down


13. Pitre CJ, Stromwall AE: Pelvic tumor presenting as chronic back pain in a young adult. J Emerg Med; 2006 Apr;30(3):287-90
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic tumor presenting as chronic back pain in a young adult.
  • A large proportion of Emergency Department visits are for chronic pain, specifically for chronic back pain.
  • This report describes the clinical presentation of a young adult with chronic back pain who exhibited new symptoms and subtle examination findings that expedited the ultimate diagnosis of pelvic chondrosarcoma.
  • [MeSH-major] Back Pain / etiology. Bone Neoplasms / diagnosis. Chondrosarcoma / diagnosis. Ilium / pathology. Sacrum / pathology

  • MedlinePlus Health Information. consumer health - Back Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16677979.001).
  • [ISSN] 0736-4679
  • [Journal-full-title] The Journal of emergency medicine
  • [ISO-abbreviation] J Emerg Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Kim JH, Hubbard NE, Ziboh V, Erickson KL: Conjugated linoleic acid reduction of murine mammary tumor cell growth through 5-hydroxyeicosatetraenoic acid. Biochim Biophys Acta; 2005 Feb 21;1687(1-3):103-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conjugated linoleic acid reduction of murine mammary tumor cell growth through 5-hydroxyeicosatetraenoic acid.
  • The goal of this study was to determine whether CLA altered mouse mammary tumor cell growth and whether specific metabolites of the lipoxygenase pathway were involved in CLA action.
  • Both t10, c12-CLA and a lipoxygenase inhibitor, but not c9, t11-CLA or linoleic acid (LA), reduced mouse mammary tumor cell viability and growth by inducing apoptosis and reducing cell proliferation. t10, c12-CLA reduced the production of the 5-lipoxygenase metabolite, 5-hydroxyeicosatetraenoic acid (5-HETE).
  • That effect was not seen with c9, t11-CLA or LA.
  • Adding 5-HETE back to tumor cells reduced the t10, c12-CLA effect on both apoptosis and cell proliferation.
  • These data suggest that t10, c12-CLA reduction of tumor cell growth may involve the suppression of the 5-lipoxygenase metabolite, 5-HETE, with subsequent effects on apoptosis and cell proliferation.
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Dose-Response Relationship, Drug. Female. Humans. Mice

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15708358.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Chemotactic Factors; 0 / Hydroxyeicosatetraenoic Acids; 0 / Linoleic Acids, Conjugated; 467RNW8T91 / 5-hydroxy-6,8,11,14-eicosatetraenoic acid
  •  go-up   go-down


15. Tabagari D, Nemsadze G, Jincharadze M, Janjalia M, Shan JS: Phase II study of bavituximab plus docetaxel in patients with locally advanced or metastatic breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3005

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PS becomes exposed on the outside surface of tumor endolethial cells.
  • Secondary objectives include time to tumor progression, duration of response, overall survival, and safety.
  • The most common AEs (regardless of severity or causality) were alopecia, epistaxis, fatigue, back pain, diarrhea, nasal dryness, infusion related reaction, arthralgia, pyrexia, stomatitis and nail bed bleeding.
  • Grade 3 drug-related AEs were back pain, headache, DVT (discontinued study treatment at week 3) and chest pain (SAE) starting during a docetaxel infusion, which recurred after completion of bavituximab, reported in one patient each.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962047.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Morgan JA, Guo A, Williams D, Guérin A, Latremouille-Viau D, Tsaneva M, Yu AP, Wu E, Signorovitch J, Demetri GD: Real world treatment patterns of gastrointestinal stromal tumor patients. J Clin Oncol; 2009 May 20;27(15_suppl):e15602

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Real world treatment patterns of gastrointestinal stromal tumor patients.
  • : e15602 Background: Imatinib is accepted as the standard first-line therapy to treat gastrointestinal stromal tumor (GIST) in patients with unresectable or metastatic disease.
  • Kaplan Meier analyses were used to estimate the rate of treatment changes over time including imatinib discontinuation, defined as a lack of imatinib supply for ≥60 days, and switching back to initial treatment.
  • Among all the switchers, 20.3% switched back to imatinib within 6 months.
  • Among switchers, most did not dose escalate before switching and many eventually switched back to imatinib.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962678.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Azab A, Azab F, Runnels J, Roccaro AM, Magnani JL, Sarkar A, Anderson KC, Lin CP, Ghobrial IM: Role of selectins in the pathogenesis of multiple myeloma. J Clin Oncol; 2009 May 20;27(15_suppl):11103

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 11103 Background: Multiple myeloma (MM) is characterized by the disseminated involvement of the bone-marrow (BM), and its progression involves a continuous circulation of the MM cells (MMCs) in the peripheral blood and homing back to the BM.
  • This provides a basis for testing the effect of the inhibitor on MM tumor progression and initiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963467.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Widemann BC, Fox E, Adamson PC, Baruchel S, Kim A, Ingle AM, Bender JG, Stempak D, Balis FM, Blaney SM: Phase I study of sorafenib in children with refractory solid tumors: A Children's Oncology Group Phase I Consortium trial. J Clin Oncol; 2009 May 20;27(15_suppl):10012

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of sorafenib in children with refractory solid tumors: A Children's Oncology Group Phase I Consortium trial.
  • We performed a phase I trial to determine the toxicities, maximum tolerated dose (MTD), pharmacokinetics (PK), and pharmacodynamics (PD) of sorafenib in children with refractory solid tumors.
  • RESULTS: 34 eligible pts [16M, median age 14.6 yrs, (range, 5-21)] with osteosarcoma (n = 8), rhabdomyosarcoma (n = 3), other sarcomas (n = 13), hepatoblastoma (n = 3), or other solid tumors (n = 7) received 1-22 cycles (median 2).
  • Grade 3 dose-limiting toxicity (DLT) occurred in 4/6 pts at the starting dose (150 mg/m<sup>2</sup>) and included hypertension (n = 1), rash/urticaria (n = 1), back pain (n = 1), thrombocytopenia (n = 1) and ALT/AST (n = 1).
  • No objective responses were observed, but 2 pts had tumor shrinkage.
  • CONCLUSIONS: The MTD of sorafenib in children with solid tumors is 200 mg/m<sup>2</sup>, similar to the adult recommended dose (400 mg).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962524.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Richardson PG, Chanan-Khan A, Lonial S, Krishnan A, Carroll M, Alsina M, Albitar M, Berman D, Kaplita S, Anderson K: Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study. J Clin Oncol; 2009 May 20;27(15_suppl):8503

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preclinical data show anti-tumor synergy between Tan and bortezomib (Bz) and suggest Tan may be neuroprotective, including reversibility of Bz-induced peripheral neuropathy (PN).
  • Median time since MM diagnosis was 50 mos with median of 5 (1-15) prior regimens.
  • Most frequent G3-4 AEs included thrombocytopenia (25%), diarrhea, anemia and fatigue (7% each), as well as back pain and AST elevation (4% each).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960855.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Altan L, Kurtoğlu Z, Yalçinkaya U, Aydinli U, Ertürk E: Brown tumor of the sacral spine in a patient with low-back pain. Rheumatol Int; 2007 Nov;28(1):77-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brown tumor of the sacral spine in a patient with low-back pain.
  • We present a case of a 44-year-old woman with an unusual location of a brown tumor in the sacral vertebrae due to parathyroid adenoma.
  • She was admitted to our clinic with the complaint of low-back pain and was later diagnosed to have a brown tumor.
  • We believe it is an interesting clinical case both because it shows a very rare localization of brown tumor and points out the importance of employing a wide clinical scope in the differential diagnosis of back pain.
  • [MeSH-major] Adenoma. Low Back Pain / surgery. Parathyroid Neoplasms. Sacrum / pathology. Spinal Neoplasms
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Lumbar Vertebrae / radiography. Magnetic Resonance Imaging / methods. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17569048.001).
  • [ISSN] 1437-160X
  • [Journal-full-title] Rheumatology international
  • [ISO-abbreviation] Rheumatol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Trumm CG, Jakobs TF, Zech CJ, Weber C, Reiser MF, Hoffmann RT: [Vertebroplasty in the treatment of back pain]. Radiologe; 2006 Jun;46(6):495-505
MedlinePlus Health Information. consumer health - Back Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vertebroplasty in the treatment of back pain].
  • CONCLUSION: PVP constitutes a safe and effective minimally invasive treatment approach to stabilize and reduce acute and chronic back pain due to osteoporotic VCF and tumor-associated osteolysis.
  • [MeSH-major] Back Pain / etiology. Back Pain / prevention & control. Bone Cements / therapeutic use. Laminectomy / methods. Spinal Cord Compression / complications. Spinal Cord Compression / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Haematol. 2006 Feb;76(2):180-1 [16405443.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Feb;22(2):373-81 [11156786.001]
  • [Cites] Radiographics. 2003 Mar-Apr;23 (2):e10 [12889460.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Nov-Dec;18(10 ):1897-904 [9403451.001]
  • [Cites] Radiology. 1996 Aug;200(2):525-30 [8685351.001]
  • [Cites] Osteoporos Int. 2004 Sep;15(9):760-5 [15138664.001]
  • [Cites] Neurochirurgie. 1987;33(2):166-8 [3600949.001]
  • [Cites] J Vasc Interv Radiol. 2002 Sep;13(9 Pt 1):883-6 [12354821.001]
  • [Cites] Radiology. 2003 Jun;227(3):662-8 [12702821.001]
  • [Cites] Radiologe. 2003 Sep;43(9):703-8 [14517599.001]
  • [Cites] J Bone Joint Surg Br. 2005 Dec;87(12):1595-604 [16326869.001]
  • [Cites] J Vasc Interv Radiol. 2004 Nov;15(11):1185-92 [15525736.001]
  • [Cites] Spine (Phila Pa 1976). 2001 Jul 15;26(14):1547-54 [11462084.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5B):3129-33 [15510600.001]
  • [Cites] Radiology. 2005 Dec;237(3):1115-9 [16304123.001]
  • [Cites] Eur Spine J. 2000 Oct;9(5):445-50 [11057541.001]
  • [Cites] Radiology. 1998 May;207 (2):349-56 [9577479.001]
  • [Cites] AJR Am J Roentgenol. 2004 Feb;182(2):319-22 [14736654.001]
  • [Cites] Radiology. 2002 Apr;223(1):121-6 [11930056.001]
  • [Cites] Cardiovasc Intervent Radiol. 2006 Mar-Apr;29(2):173-8 [16362467.001]
  • [Cites] Rheumatology (Oxford). 2000 Dec;39(12):1410-4 [11136886.001]
  • [Cites] Radiologe. 2003 Sep;43(9):729-34 [14517603.001]
  • [Cites] In Vivo. 2005 Nov-Dec;19(6):1055-60 [16277022.001]
  • [Cites] J Rheumatol Suppl. 2003 Aug;67:26-31 [12926648.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Jun-Jul;23(6):913-7 [12063215.001]
  • [Cites] J Rheumatol. 1999 Oct;26(10 ):2222-8 [10529144.001]
  • [Cites] Spine (Phila Pa 1976). 2002 Oct 1;27(19):2173-8; discussion 2178-9 [12394934.001]
  • [Cites] J Vasc Interv Radiol. 2003 Sep;14(9 Pt 2):S311-5 [14514838.001]
  • [Cites] Eur Spine J. 2001 Oct;10 Suppl 2:S205-13 [11716020.001]
  • [Cites] Eur Spine J. 2006 Jul;15(7):1050-67 [16429288.001]
  • [Cites] Anaesthesia. 2002 Dec;57(12):1229-30 [12437738.001]
  • [Cites] J Vasc Interv Radiol. 2003 Jun;14 (6):683-96 [12817036.001]
  • [Cites] Radiology. 2003 Feb;226(2):366-72 [12563127.001]
  • [Cites] Clin Med Res. 2003 Apr;1(2):93-9 [15931294.001]
  • [Cites] Am J Med. 2003 Mar;114(4):257-65 [12681451.001]
  • [Cites] Radiol Clin North Am. 1998 May;36(3):533-46 [9597071.001]
  • [Cites] Radiology. 1996 Apr;199(1):241-7 [8633152.001]
  • (PMID = 16786386.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Bone Cements
  • [Number-of-references] 38
  •  go-up   go-down


22. Deng XL, Liu XY, Xu N: Comparative study on low back pain misdiagnosed as spondyloarthropathy. Clin Rheumatol; 2009 Aug;28(8):893-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative study on low back pain misdiagnosed as spondyloarthropathy.
  • This study aims to investigate features of different diseases with low back pain misdiagnosed as spondyloarthropathy so as to improve the accuracy of diagnosis for spondyloarthropathy.
  • The final diagnoses of these 24 cases were listed below: four malignant tumors (retroperitoneal adipose sarcoma, advanced gastric carcinoma, ovarian papillary epithelioma, acute lymphocytic leukemia), six benign tumors (two parathyroid adenoma with hyperparathyroidism, one intraspinal lipoma, intraspinal ependymomas, sacral tubulocyst, and intraspinal schwannoglioma, respectively).
  • Among patients with tumor, all except three patients had persistent low back pain without morning stiffness, which aggravated at night and could not be relieved by rest or exercise.
  • Eleven patients had inflammatory low back pain defined by Calin.
  • From the data, we could see that the clinical features of different diseases with low back pain were different from each other and from those of spondyloarthropathy.
  • [MeSH-major] Diagnostic Errors. Low Back Pain / etiology. Neoplasms / diagnosis. Severity of Illness Index. Spondylarthropathies / complications. Spondylarthropathies / diagnosis
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Female. HLA-B27 Antigen / analysis. Humans. Male. Medical Audit. Middle Aged. Pain, Referred / etiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19449145.001).
  • [ISSN] 1434-9949
  • [Journal-full-title] Clinical rheumatology
  • [ISO-abbreviation] Clin. Rheumatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / HLA-B27 Antigen
  •  go-up   go-down


23. Weinrich M, Pistorius GA, Wagner M, Schilling MK, Maurer CA: [An adrenal pseudocyst as the cause of chronic back pain]. Orthopade; 2005 Dec;34(12):1263-6
MedlinePlus Health Information. consumer health - Back Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An adrenal pseudocyst as the cause of chronic back pain].
  • We present the case of a 36 year old female patient with a 3 month history of severe lower back pain without improvement after physiotherapy and analgesic drug therapy.
  • A cystic tumor projecting on the posterior area of the right liver lobe was seen using ultrasound.
  • MRI-scan showed an extrahepatic localization of the tumor.
  • Intraoperatively, the tumor was located in the right adrenal gland which was then removed.
  • [MeSH-major] Adrenal Gland Diseases / diagnosis. Adrenal Gland Diseases / surgery. Back Pain / diagnosis. Back Pain / prevention & control. Cysts / diagnosis. Cysts / surgery

  • MedlinePlus Health Information. consumer health - Adrenal Gland Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16205888.001).
  • [ISSN] 0085-4530
  • [Journal-full-title] Der Orthopäde
  • [ISO-abbreviation] Orthopade
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


24. Verdin V, Preud'Homme L, Lemaire V, Jacquemin D: [Giant lipoma on the back]. Rev Med Liege; 2009 Jul-Aug;64(7-8):414-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant lipoma on the back].
  • Solitary lipoma is the most frequent soft tissue tumor, often appearing between 40 and 60 years of age.
  • The diagnosis is primarily clinical.
  • Surgical biopsy is recommended if the diagnosis cannot be asserted by the clinic or an imagery.
  • [MeSH-major] Back / pathology. Back / surgery. Lipoma / pathology
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Female. Humans. Quality of Life. Scapula / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19777924.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


25. Aydeniz A, Erkutlu I, Altindağ O, Küçükoğlu B, Gürsoy S: Severe neck and back pain in adolescence: remember osteoblastoma. Rheumatol Int; 2010 Jul;30(9):1243-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe neck and back pain in adolescence: remember osteoblastoma.
  • Osteoblastoma is a rare benign tumor of the bone.
  • A 15-year-old boy presented with severe neck and back pain and was followed up for myofascial pain syndrome for 12 months.
  • The tumor was resected by a spinal surgeon and histologic examination revealed osteoblastoma.
  • [MeSH-minor] Adolescent. Back Pain / radiography. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Scoliosis / radiography. Thoracic Vertebrae / pathology. Thoracic Vertebrae / radiography. Thoracic Vertebrae / surgery. Treatment Outcome. X-Rays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19582457.001).
  • [ISSN] 1437-160X
  • [Journal-full-title] Rheumatology international
  • [ISO-abbreviation] Rheumatol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Quaedvlieg PJ, Frank J, Vermeulen AH, Toonstra J, van Neer FJ: Giant ceribriform intradermal nevus on the back of a newborn. Pediatr Dermatol; 2008 Jan-Feb;25(1):43-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant ceribriform intradermal nevus on the back of a newborn.
  • A male newborn had a large cerebriform tumor covering his shoulders and almost the entire surface of his back.
  • After exclusion of further abnormalities, the diagnosis of cerebriform intradermal nevus was made.
  • The clinical manifestation of cerebriform intradermal nevi as giant melanocytic nevi on the back is extremely rare, with only one instance reported to date.
  • [MeSH-minor] Back. Biopsy, Needle. Humans. Immunohistochemistry. Infant, Newborn. Male. Monitoring, Physiologic / methods. Nevus, Pigmented / congenital. Nevus, Pigmented / pathology. Nevus, Pigmented / therapy. Prognosis. Risk Assessment

  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18304152.001).
  • [ISSN] 1525-1470
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Yang YW, Shih IH, Huang YH, Kuo TT, Hong HS: Mixed-type neurothekeoma presenting with an unusual clinical appearance of multiple satellite lesions on the back. Dermatol Surg; 2005 Jun;31(6):720-2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed-type neurothekeoma presenting with an unusual clinical appearance of multiple satellite lesions on the back.
  • BACKGROUND: Neurothekeoma is a rare cutaneous neoplasm, often occurring as a nondescript cutaneous nodule on the central face, shoulders, and upper extremities.
  • METHODS: We report a 29-year-old female who developed an asymptomatic, red, dermal nodule with satellite papules on the back over a period of 6 months.
  • RESULTS: The coalescing papules on the back were excised, and the histopathology and immunohistochemical study revealed a mixed-type neurothekeoma.
  • The case is interesting because of the unusual clinical manifestation of one dermal tumor with several satellite lesions.
  • [MeSH-major] Neurothekeoma / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Back. Female. Humans. Immunohistochemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15996430.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Costantini M, Morasso G, Montella M, Borgia P, Cecioni R, Beccaro M, Sguazzotti E, Bruzzi P, ISDOC Study Group: Diagnosis and prognosis disclosure among cancer patients. Results from an Italian mortality follow-back survey. Ann Oncol; 2006 May;17(5):853-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and prognosis disclosure among cancer patients. Results from an Italian mortality follow-back survey.
  • This study estimates the proportion of Italian who died of cancer who had received information about diagnosis and prognosis, and explores the variables associated with disclosure.
  • MATERIALS AND METHODS: This is a mortality follow-back survey of 1271 non-professional caregivers of Italians who died of cancer in 2002, representative of the approximate 160 000 Italian annual cancer deaths.
  • Caregivers were interviewed after the patient's death about the process of diagnosis and prognosis disclosure.
  • RESULTS: It was estimated that 37% of people who died of cancer had received information about diagnosis and 13% about poor prognosis.
  • A consistent proportion, although non-informed, knew the diagnosis (29%) and the poor prognosis (50%).
  • The probability to be informed was higher for patients living in the north of Italy, young, well educated, with longer survival, and with breast or head and neck tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16551764.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


29. Jacobsen S, Birkelund Y: Improved resolution and reduced clutter in ultra-wideband microwave imaging using cross-correlated back projection: experimental and numerical results. Int J Biomed Imaging; 2010;2010:781095

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved resolution and reduced clutter in ultra-wideband microwave imaging using cross-correlated back projection: experimental and numerical results.
  • Detection of tumors within the breast is achieved by some selected focusing technique.
  • Image formation algorithms are tailored to enhance tumor responses and reduce early-time and late-time clutter associated with skin reflections and heterogeneity of breast tissue.
  • In this contribution, we evaluate the performance of the so-called cross-correlated back projection imaging scheme by using a scanning system in phantom experiments.
  • Successful detection of a 7 mm diameter cylindrical tumor immersed in a low permittivity medium was achieved in all cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Physiol Meas. 2009 Jun;30(6):S121-36 [19491436.001]
  • [Cites] Phys Med Biol. 2009 Feb 7;54(3):641-50 [19124946.001]
  • [Cites] IEEE Trans Biomed Eng. 2008 Jan;55(1):237-46 [18232367.001]
  • [Cites] Phys Med Biol. 2007 Oct 21;52(20):6093-115 [17921574.001]
  • [Cites] Radiographics. 1998 Sep-Oct;18(5):1137-54; quiz 1243-4 [9747612.001]
  • [Cites] Med Biol Eng Comput. 2004 Sep;42(5):581-90 [15503957.001]
  • [Cites] IEEE Trans Biomed Eng. 2002 Aug;49(8):812-22 [12148820.001]
  • [Cites] IEEE Trans Biomed Eng. 1998 Dec;45(12):1470-9 [9835195.001]
  • [Cites] N Engl J Med. 1998 Apr 16;338(16):1089-96 [9545356.001]
  • [Cites] IEEE Trans Med Imaging. 2005 Oct;24(10):1308-22 [16229417.001]
  • (PMID = 21331362.001).
  • [ISSN] 1687-4196
  • [Journal-full-title] International journal of biomedical imaging
  • [ISO-abbreviation] Int J Biomed Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3035806
  •  go-up   go-down


30. Ohtori S, Inoue G, Ito T, Koshi T, Ozawa T, Doya H, Saito T, Moriya H, Takahashi K: Tumor necrosis factor-immunoreactive cells and PGP 9.5-immunoreactive nerve fibers in vertebral endplates of patients with discogenic low back Pain and Modic Type 1 or Type 2 changes on MRI. Spine (Phila Pa 1976); 2006 Apr 20;31(9):1026-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor necrosis factor-immunoreactive cells and PGP 9.5-immunoreactive nerve fibers in vertebral endplates of patients with discogenic low back Pain and Modic Type 1 or Type 2 changes on MRI.
  • STUDY DESIGN: Immunohistochemistry for tumor necrosis factor (TNF) and protein gene product (PGP) 9.5 in vertebral endplates of patients with discogenic low back pain and Modic Type 1 or Type 2 endplate changes on MRI.
  • OBJECTIVES: To examine whether inflammatory cytokines and nerve in-growth into the vertebral endplate are associated with discogenic low back pain.
  • SUMMARY AND BACKGROUND DATA: Degenerated discs and endplate abnormalities can be a cause of discogenic low back pain.
  • However, the presence of TNF-immunoreactive cells and PGP 9.5-immunoreactive nerve fibers has not been studied in patients with discogenic low back pain and endplate changes on MRI.
  • METHODS: Eighteen endplates showing either normal intensity signals on MRI (endplate change -), Modic Type 1 signals (low intensity on T1-weighted spin-echo images), or Modic Type 2 signals (high intensity) from patients with discogenic low back pain (n = 14) or controls requiring surgery for other back problems (n = 4; scoliosis and traumatic injury of vertebra) were harvested during surgery.
  • TNF expression and PGP 9.5-positive nerve in-growth in abnormal endplates may be a cause of low back pain.
  • [MeSH-major] Intervertebral Disc / metabolism. Intervertebral Disc Displacement / metabolism. Low Back Pain / metabolism. Lumbar Vertebrae. Nerve Fibers / metabolism. Tumor Necrosis Factor-alpha / metabolism. Ubiquitin Thiolesterase / metabolism

  • MedlinePlus Health Information. consumer health - Herniated Disk.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16641780.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; EC 3.1.2.15 / UCHL1 protein, human; EC 3.1.2.15 / Ubiquitin Thiolesterase
  •  go-up   go-down


31. Davis MA, Bove GM: A case of pheochromocytoma presenting as low back pain. J Manipulative Physiol Ther; 2007 Oct;30(8):598-601
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of pheochromocytoma presenting as low back pain.
  • OBJECTIVE: This case report describes and discusses a patient with a pheochromocytoma who presented to a chiropractic office with low back pain.
  • CLINICAL FEATURES: The patient is a 51-year-old woman who was self-referred to our chiropractic service with low back pain that appeared to be musculoskeletal in nature.
  • Her initial back symptoms resolved with tumor excision.
  • CONCLUSION: Pheochromocytomas are rare catecholamine-producing tumors of the adrenal glands that can mimic musculoskeletal conditions such as low back pain.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Low Back Pain / etiology. Manipulation, Chiropractic / methods. Pheochromocytoma / diagnosis
  • [MeSH-minor] Catecholamines / metabolism. Diagnosis, Differential. Female. Humans. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Chiropractic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17996552.001).
  • [ISSN] 1532-6586
  • [Journal-full-title] Journal of manipulative and physiological therapeutics
  • [ISO-abbreviation] J Manipulative Physiol Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Catecholamines
  •  go-up   go-down


32. Cho JC, Miller A, Kettner NW: Cervical ependymoma in a male adolescent with neck and back pain. J Manipulative Physiol Ther; 2009 Oct;32(8):695-700
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical ependymoma in a male adolescent with neck and back pain.
  • OBJECTIVE: This case study addresses the clinical presentation, imaging manifestations, and management of an intramedullary ependymoma in an adolescent who presented for chiropractic evaluation with severe neck and back pain.
  • The atypical manifestations of this disorder are emphasized.
  • CLINICAL FEATURES: A 16-year-old male adolescent presented with severe neck and back pain and diffuse paresthesia extending into the dorsum of the forearm and wrist bilaterally.
  • INTERVENTION AND OUTCOME: The patient underwent a successful resection of the tumor with minimal neurological deficit.
  • At 4 months after resection, the follow-up examination yielded minimal discomfort in the neck and upper back, however there was severe cervical kyphosis.
  • CONCLUSION: Although it is a rare and slow growing neoplasm, early detection is critical for optimal postoperative functional outcome that is directly related to the preoperative functional status.
  • [MeSH-major] Back Pain / surgery. Ependymoma / diagnosis. Ependymoma / surgery. Neck Pain / surgery. Spinal Cord Neoplasms / diagnosis. Spinal Cord Neoplasms / surgery

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Back Pain.
  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19836608.001).
  • [ISSN] 1532-6586
  • [Journal-full-title] Journal of manipulative and physiological therapeutics
  • [ISO-abbreviation] J Manipulative Physiol Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Skroza N, Panetta C, Schwartz RA, Balzani A, Rota C, Buccheri EM, Alfano C, Innocenzi D: Giant meta-typical carcinoma: an unusual tumor. Acta Dermatovenerol Croat; 2006;14(1):46-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant meta-typical carcinoma: an unusual tumor.
  • It is typically located on the back and face, often with clinical features of basal cell carcinoma but tending to be more aggressive with enhanced prospects of lymph node or distant metastases.
  • Our report describes a huge neglected MTC of the back of ten-year duration, a giant ulcero-vegetative tumor measuring 20 x 25 cm.
  • Histologic examination of specimens from the margins and periphery revealed aspects of both basal and squamous cell carcinoma, while the ulcerated center showed sclerotic tissue without tumor.
  • This may have been related to an intense inflammatory host response with elimination of neoplastic tissue and consequent local sclerosis evident in the central tumor-free portion.
  • This central tumor regression is to our knowledge a unique finding in MTC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16603102.001).
  • [ISSN] 1330-027X
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


34. Shostak NA, Pravdiuk NG, Koriakina IN: [Low back pain in young subjects: a new approach to therapy]. Ter Arkh; 2009;81(10):52-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Low back pain in young subjects: a new approach to therapy].
  • SUBJECTS AND METHODS: Fifty patients (males and females) aged 18-35 years who had acute and chronic low back pain (LBP) (visual analog scale (VAS), > 40 mm) associated with DDD were enrolled in the study.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Antibodies, Monoclonal / therapeutic use. Cyclooxygenase Inhibitors / therapeutic use. Intervertebral Disc Degeneration. Low Back Pain / drug therapy. Tumor Necrosis Factor-alpha / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19947442.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antibodies, Monoclonal; 0 / Artrofoon; 0 / Cyclooxygenase Inhibitors; 0 / Sulfonamides; 0 / Tumor Necrosis Factor-alpha; V4TKW1454M / nimesulide
  •  go-up   go-down


35. Chohan MO, Rehman T, Cerilli LA, Devers K, Medina-Flores R, Turner P: Metastatic epithelioid trophoblastic tumor involving the spine. Spine (Phila Pa 1976); 2010 Sep 15;35(20):E1072-5
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for epithelioid trophoblastic tumor .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic epithelioid trophoblastic tumor involving the spine.
  • OBJECTIVE: We report the first case of epithelioid trophoblastic tumor (ETT) presenting as primary metastasis to the spine.
  • SUMMARY OF BACKGROUND DATA: ETT is an extremely rare form of gestational trophoblastic neoplasm with less than 100 cases reported in the literature.
  • A 36-year-old, postpartum woman presented with severe low back pain and was found to have a contrast-enhancing lesion in lower thoracic spine subsequently confirmed as ETT.
  • CONCLUSION: This first report of metastasis of ETT to the spine adds significant new information to the growing literature of this rare and newly identified tumor.
  • It also alerts the neurosurgeon into considering the diagnosis with appropriate clinical presentation.
  • As more number of cases of nervous system involvement with this tumor are reported, crucial information on prognostic factors and treatment regimens will emerge.
  • [MeSH-minor] Adult. Combined Modality Therapy. Drug Therapy. Fatal Outcome. Female. Humans. Low Back Pain / etiology. Magnetic Resonance Imaging. Neurosurgical Procedures. Pregnancy. Radiculopathy / etiology. Thoracic Vertebrae / radiography

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20802395.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


36. Celli P, Trillò G, Ferrante L: Extrathecal intraradicular nerve sheath tumor. J Neurosurg Spine; 2005 Jul;3(1):1-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extrathecal intraradicular nerve sheath tumor.
  • OBJECT: The purpose of this study was to analyze the clinical profile of patients harboring extrathecal and intraradicular nerve sheath tumors (NSTs), located inside the sleeve of an extrathecal nerve root and very often within the proximal portion of the spinal nerve, and to evaluate the incidence of long-term dysfunction of the tumor-affected roots if resected.
  • These tumors have not received particular attention in the literature.
  • Data pertaining to clinical features, tumor characteristics, and results of surgery were analyzed.
  • In the authors' experience, neither deafferentation pain nor severe radicular weakness occurs after division of the nerve root harboring the tumor.
  • [MeSH-major] Neurilemmoma / complications. Neurilemmoma / diagnosis. Neurofibroma / complications. Neurofibroma / diagnosis. Spinal Cord Neoplasms / complications. Spinal Cord Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Back Pain / etiology. Cervical Vertebrae. Female. Follow-Up Studies. Humans. Lumbar Vertebrae. Male. Middle Aged. Retrospective Studies. Spinal Nerve Roots. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16122015.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Justinger C, Weinrich M, Katoh M, Schilling MK: [Chronic back pain resulting from a retroperitoneal lymphangioma]. Schmerz; 2008 Aug;22(4):465-7
MedlinePlus Health Information. consumer health - Back Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chronic back pain resulting from a retroperitoneal lymphangioma].
  • A 39-year-old female patient presented with a 3-year history of lower back pain which had not been alleviated by pain treatment combined with physiotherapy.
  • Radiological findings were normal with the exception of a cystic paravertebral tumor in the left retroperitoneum.
  • [MeSH-major] Back Pain / etiology. Lymphangioma / diagnosis. Retroperitoneal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Pain Measurement. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lymphangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483749.001).
  • [ISSN] 0932-433X
  • [Journal-full-title] Schmerz (Berlin, Germany)
  • [ISO-abbreviation] Schmerz
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


38. Ip YT, Yuan JQ, Cheung H, Chan JK: Sporadic hemangioblastoma of the kidney: an underrecognized pseudomalignant tumor? Am J Surg Pathol; 2010 Nov;34(11):1695-700
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic hemangioblastoma of the kidney: an underrecognized pseudomalignant tumor?
  • Hemangioblastoma is a benign tumor that can occur sporadically, or in association with von Hippel-Lindau disease in approximately one-quarter of the cases.
  • This report describes 2 cases of sporadic renal hemangioblastoma, with 1 patient presenting with hematuria and polycythemia, and the other low back pain.
  • Histologically, the tumors were circumscribed, and composed of sheets of large polygonal cells traversed by arborizing thin-walled blood vessels.
  • Many of the tumor cells showed pleomorphic nuclei, but the mitotic figures were rare.
  • The diagnosis of hemangioblastoma was confirmed by negative immunostaining for cytokeratin, and positive staining for α-inhibin, S100, and neuron-specific enolase.
  • This benign neoplasm which can be mistaken for various malignancies such as renal cell carcinoma, epithelioid angiomyolipoma, adrenal cortical carcinoma, and paraganglioma, deserves wider recognition for its occurrence as a primary renal tumor.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Hematuria / etiology. Humans. Immunohistochemistry. Inhibins / analysis. Keratins / analysis. Low Back Pain / etiology. Male. Middle Aged. Nephrectomy. Phosphopyruvate Hydratase / analysis. Polycythemia / etiology. S100 Proteins / analysis

  • Genetic Alliance. consumer health - Hemangioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2011 Apr;35(4):623-4 [21378542.001]
  • (PMID = 20924277.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins; 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins; 68238-35-7 / Keratins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


39. Sultan I, Masarweh M, Ismael T, Al-Hussaini M, Almousa A, Ali HM, Rodriguez-Galindo C, Ghandour K: From upfront nephrectomy to preoperative chemotherapy and back: a single institution experience in the treatment of Wilms tumor. J Pediatr Hematol Oncol; 2009 May;31(5):333-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From upfront nephrectomy to preoperative chemotherapy and back: a single institution experience in the treatment of Wilms tumor.
  • BACKGROUND: Over the past decades, 2 different approaches for the treatment of Wilms tumor have emerged: upfront nephrectomy (UN) and preoperative chemotherapy (PC), with adjuvant treatment adjusted to stage, histology, and chemotherapy response.
  • RESULTS: Thirty-six children (20 males) with Wilms tumor were studied.
  • Nineteen patients (53%) were treated according to the International Society of Paediatric Oncology 93-01/German Pediatric Oncology Hematology, Group protocol (PC group) and 17 (47%) according to the National Wilms' Tumor Study-5 (UN group).
  • Although selecting a specific protocol for Wilms tumor is important, the development of surgical expertise and referral to specialized centers takes priority.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Kidney Neoplasms / drug therapy. Kidney Neoplasms / surgery. Nephrectomy. Wilms Tumor / drug therapy. Wilms Tumor / surgery
  • [MeSH-minor] Adolescent. Carboplatin / administration & dosage. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Infant. Kaplan-Meier Estimate. Male. Neoplasm Staging. Preoperative Care. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415012.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; SIOP protocol
  •  go-up   go-down


40. Bastaki W, Mothaffer F, Varro J, Al-Ghanim M, Malak L, Ayyash E, Asfar S: Primary hepatic carcinoid tumor. Med Princ Pract; 2005 Jul-Aug;14(4):288-91
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatic carcinoid tumor.
  • OBJECTIVES: To describe a rare case of primary carcinoid tumor of the liver and its management.
  • CLINICAL PRESENTATION AND INTERVENTIONS: A 44-year-old Nigerian male presented with a big inoperable liver mass, which proved to be a carcinoid tumor by fine needle aspiration cytology.
  • Percutaneous embolization of the tumor followed by complete dearterializations of the liver seemed to have halted the growth of the tumor.
  • The patient remained well with normal liver function tests for 56 months when he decided to go back to his country.
  • [MeSH-major] Carcinoid Tumor / therapy. Embolization, Therapeutic. Liver Neoplasms / therapy

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 15961944.001).
  • [ISSN] 1011-7571
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


41. Adema GJ: Dendritic cells from bench to bedside and back. Immunol Lett; 2009 Feb 21;122(2):128-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cells from bench to bedside and back.
  • Several mouse models have demonstrated that the immunological outcome is depending on the DC activation state; mature immune-activating DC protect mice from a tumor or pathogen while tolerogenic DC induces tolerance against transplanted tissues.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19121337.001).
  • [ISSN] 1879-0542
  • [Journal-full-title] Immunology letters
  • [ISO-abbreviation] Immunol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Cancer Vaccines; 0 / Cytokines; 0 / Toll-Like Receptors
  • [Number-of-references] 15
  •  go-up   go-down


42. Wang H, Ahrens C, Rief W, Schiltenwolf M: Influence of comorbidity with depression on interdisciplinary therapy: outcomes in patients with chronic low back pain. Arthritis Res Ther; 2010;12(5):R185
MedlinePlus Health Information. consumer health - Depression.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of comorbidity with depression on interdisciplinary therapy: outcomes in patients with chronic low back pain.
  • INTRODUCTION: Our previous work showed higher tumour necrosis factor (TNF)-α levels in patients with chronic low back pain (cLBP) compared to healthy controls.
  • In this study we investigated the influence of depression on therapy outcomes such as TNF-α serum levels, pain intensity and back function in patients with cLBP.
  • The clinical outcomes such as pain intensity, as well as back function, sleep, exercise, alcohol and nicotine consumption were documented.
  • At T0, both cLBP patients with (cLBP+DE) and without (cLBP) depression showed significantly higher TNF-α serum levels (P = 0.002 for cLBP+DE, P = 0.004 for cLBP) than healthy controls (HC) that normalized after 10 days of therapy and remained similar to healthy controls.
  • CONCLUSIONS: Depression as a comorbidity to chronic low back pain did not influence the serum TNF-α level in the course of six months, but seemed to affect the success of therapy. cLBP patients with comorbidity of depression benefit from multidisciplinary pain therapy not only to the same extent but also to a greater degree than cLBP patients without depression.
  • [MeSH-major] Depression / epidemiology. Depression / therapy. Low Back Pain / epidemiology. Low Back Pain / therapy. Tumor Necrosis Factor-alpha / blood

  • Genetic Alliance. consumer health - Depression.
  • Genetic Alliance. consumer health - Dysthmia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Life Sci. 1999;65(17):1773-86 [10576557.001]
  • [Cites] Health Psychol. 2007 Jan;26(1):1-9 [17209691.001]
  • [Cites] Psychoneuroendocrinology. 2000 Nov;25(8):785-97 [10996474.001]
  • [Cites] Inflamm Res. 2007 Jan;56(1):32-7 [17334668.001]
  • [Cites] Curr Pain Headache Rep. 2007 Apr;11(2):98-103 [17367587.001]
  • [Cites] Schizophr Res. 2007 May;92(1-3):207-10 [17337162.001]
  • [Cites] J Consult Clin Psychol. 2007 Jun;75(3):475-88 [17563164.001]
  • [Cites] Keio J Med. 2007 Jun;56(2):48-52 [17609588.001]
  • [Cites] Curr Opin Anaesthesiol. 2007 Oct;20(5):485-9 [17873602.001]
  • [Cites] Indian J Physiol Pharmacol. 2007 Jan-Mar;51(1):69-75 [17877295.001]
  • [Cites] Ann Intern Med. 2007 Oct 2;147(7):492-504 [17909210.001]
  • [Cites] Ann Intern Med. 2007 Oct 2;147(7):505-14 [17909211.001]
  • [Cites] Z Rheumatol. 2007 Oct;66(6):473-83 [17849126.001]
  • [Cites] Neuroimmunomodulation. 2007;14(3-4):206-12 [18073516.001]
  • [Cites] Clin J Pain. 2008 Mar-Apr;24(3):273-8 [18287835.001]
  • [Cites] Int J Geriatr Psychiatry. 2008 Apr;23(4):347-55 [17979214.001]
  • [Cites] J Rheumatol. 2008 Jul;35(7):1366-70 [18528959.001]
  • [Cites] Gen Hosp Psychiatry. 2009 Mar-Apr;31(2):116-22 [19269531.001]
  • [Cites] Pain. 2001 Jan;89(2-3):199-206 [11166476.001]
  • [Cites] J Affect Disord. 2001 Mar;63(1-3):35-41 [11246078.001]
  • [Cites] J Biol Chem. 2001 Nov 23;276(47):43901-8 [11572871.001]
  • [Cites] Front Biosci (Landmark Ed). 2009;14:5031-51 [19482603.001]
  • [Cites] Disabil Rehabil. 2002 Apr 15;24(6):334-40 [12017467.001]
  • [Cites] Manag Care. 2002 Aug;11(8 Suppl):7-10; discussion 21-5 [12233202.001]
  • [Cites] Pain. 2002 Sep;99(1-2):313-21 [12237210.001]
  • [Cites] Brain Behav Immun. 2002 Oct;16(5):569-74 [12401470.001]
  • [Cites] Arch Gen Psychiatry. 2003 Jan;60(1):39-47 [12511171.001]
  • [Cites] Brain. 2003 Feb;126(Pt 2):438-50 [12538410.001]
  • [Cites] Biol Psychiatry. 2003 Aug 1;54(3):399-409 [12893114.001]
  • [Cites] Arch Intern Med. 2003 Nov 10;163(20):2433-45 [14609780.001]
  • [Cites] Exerc Immunol Rev. 2003;9:70-93 [14686096.001]
  • [Cites] J Neurosci. 2004 Jan 28;24(4):964-71 [14749441.001]
  • [Cites] Z Orthop Ihre Grenzgeb. 2004 Mar-Apr;142(2):146-52 [15106058.001]
  • [Cites] Spine (Phila Pa 1976). 1983 Mar;8(2):141-4 [6222486.001]
  • [Cites] Pain. 1991 Aug;46(2):177-84 [1749640.001]
  • [Cites] Pain. 1993 Apr;53(1):95-103 [8316396.001]
  • [Cites] Br J Psychiatry. 1997 Nov;171:444-8 [9463603.001]
  • [Cites] Med Clin North Am. 1999 May;83(3):737-60, vii [10386123.001]
  • [Cites] Inflamm Res. 1999 Jul;48(7):369-79 [10450786.001]
  • [Cites] Ann Rheum Dis. 1957 Dec;16(4):494-502 [13498604.001]
  • [Cites] J Neurochem. 2004 Dec;91(6):1493-500 [15584925.001]
  • [Cites] Expert Opin Pharmacother. 2005 Mar;6(3):369-76 [15794728.001]
  • [Cites] Clin Rheumatol. 2004 Dec;23(6):566; author reply 567 [15801083.001]
  • [Cites] Behav Brain Res. 2005 May 7;160(1):125-34 [15836907.001]
  • [Cites] Int J Psychiatry Med. 2005;35(1):27-39 [15977943.001]
  • [Cites] Eur J Pain. 2005 Aug;9(4):463-84 [15979027.001]
  • [Cites] Eur Spine J. 2006 Jul;15(7):1083-92 [16311751.001]
  • [Cites] J Affect Disord. 2006 Nov;96(1-2):107-10 [16782205.001]
  • [Cites] Scand J Rheumatol. 2006 Sep-Oct;35(5):363-7 [17062436.001]
  • [Cites] Neuroimmunomodulation. 2000;7(1):27-35 [10601816.001]
  • (PMID = 20937108.001).
  • [ISSN] 1478-6362
  • [Journal-full-title] Arthritis research & therapy
  • [ISO-abbreviation] Arthritis Res. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ PMC2991020
  •  go-up   go-down


43. Wang H, Schiltenwolf M, Buchner M: The role of TNF-alpha in patients with chronic low back pain-a prospective comparative longitudinal study. Clin J Pain; 2008 Mar-Apr;24(3):273-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of TNF-alpha in patients with chronic low back pain-a prospective comparative longitudinal study.
  • OBJECTIVES: In this prospective longitudinal clinical study with a matched-pair design, we evaluated the role of tumor necrosis factor-alpha (TNF-alpha) and its clinical relevance in patients with chronic low back pain.
  • METHODS: One hundred twenty patients with chronic low back pain were matched to a healthy control group.
  • DISCUSSION: TNF-alpha seems to have a significant role in patients with chronic low back pain.
  • [MeSH-major] Low Back Pain / blood. Low Back Pain / therapy. Tumor Necrosis Factor-alpha / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18287835.001).
  • [ISSN] 0749-8047
  • [Journal-full-title] The Clinical journal of pain
  • [ISO-abbreviation] Clin J Pain
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


44. Orth JD, McNiven MA: Get off my back! Rapid receptor internalization through circular dorsal ruffles. Cancer Res; 2006 Dec 1;66(23):11094-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Get off my back! Rapid receptor internalization through circular dorsal ruffles.
  • Most importantly, the formation of these structures may be less frequent in tumor cells and thereby have significant effects on receptor signaling and cell growth.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145849.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cortactin; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.5 / Dynamins
  • [Number-of-references] 22
  •  go-up   go-down


45. Kraychete DC, Sakata RK, Issy AM, Bacellar O, Santos-Jesus R, Carvalho EM: Serum cytokine levels in patients with chronic low back pain due to herniated disc: analytical cross-sectional study. Sao Paulo Med J; 2010;128(5):259-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum cytokine levels in patients with chronic low back pain due to herniated disc: analytical cross-sectional study.
  • In order to evaluate whether there is any association between disc herniation and elevated cytokine levels, we measured cytokine levels in patients with chronic low back pain and in healthy subjects.
  • METHODS: cytokine levels were measured using the enzyme-linked immunosorbent assay (ELISA) technique on 23 patients with low back pain (G1) and on 10 healthy subjects (G2).
  • RESULTS: the levels of tumor necrosis factor-alpha [TNF-alpha] (G1 = 5.6 ± 2.3 pg/ml; G2 = 1.6 ± 0.5 pg/ml; P = 0.01) and interleukin-6 [IL-6] (G1 = 4.1 ± 3.0 pg/ml; G2 = 0.9 ± 0.4 pg/ml; P = 0.01) were higher in G1.
  • There were no statistically significant differences in relation to interleukin-1 [IL-1] (G1 = 0.5 ± 0.3 pg/ml; G2 = 0.5 ± 0.1 pg/ml; P = 1) or soluble tumor necrosis factor receptor [sTNF-R] (G1 = 572 pg/ml ± 36; G2 = 581 ± 50 pg/ml; P = 0.87).
  • CONCLUSION: The patients with chronic low back pain due to disc herniation presented higher levels of TNF-alpha and IL-6, but not of IL-1 or sTNF-R.
  • [MeSH-major] Cytokines / blood. Intervertebral Disc Displacement / complications. Low Back Pain / blood. Lumbar Vertebrae
  • [MeSH-minor] Adult. Epidemiologic Methods. Female. Humans. Interleukin-1 / blood. Interleukin-6 / blood. Male. Receptors, Tumor Necrosis Factor, Type I / blood. Tumor Necrosis Factor-alpha / blood

  • MedlinePlus Health Information. consumer health - Herniated Disk.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21181064.001).
  • [ISSN] 1806-9460
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-1; 0 / Interleukin-6; 0 / Receptors, Tumor Necrosis Factor, Type I; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


46. Capozzi O, Purgato S, D'Addabbo P, Archidiacono N, Battaglia P, Baroncini A, Capucci A, Stanyon R, Della Valle G, Rocchi M: Evolutionary descent of a human chromosome 6 neocentromere: a jump back to 17 million years ago. Genome Res; 2009 May;19(5):778-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolutionary descent of a human chromosome 6 neocentromere: a jump back to 17 million years ago.
  • The neocentromere we discovered, consequently, has jumped back to the ancestral position, where a latent centromere-forming potentiality persisted for at least 17 Myr.
  • [MeSH-minor] Animals. Autoantigens / genetics. Cell Line, Tumor. Chromosomal Proteins, Non-Histone / genetics. Genetic Variation. Genome, Human. Genomics. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Pedigree

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1982 Mar 19;215(4539):1525-30 [7063861.001]
  • [Cites] Chromosoma. 2009 Apr;118(2):269-77 [19048265.001]
  • [Cites] Hum Genet. 1993 Feb;90(6):577-83 [8444464.001]
  • [Cites] Cytogenet Cell Genet. 1997;78(3-4):260-71 [9465900.001]
  • [Cites] Nature. 2001 Feb 15;409(6822):860-921 [11237011.001]
  • [Cites] Methods. 2002 Jan;26(1):48-56 [12054904.001]
  • [Cites] Chromosoma. 2002 Dec;111(5):348-56 [12474064.001]
  • [Cites] Ann Genet. 2003 Jan-Mar;46(1):45-8 [12818529.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7672-7 [12810957.001]
  • [Cites] Mol Biol Evol. 2003 Sep;20(9):1506-12 [12832646.001]
  • [Cites] Genome Res. 2003 Sep;13(9):2059-68 [12915487.001]
  • [Cites] Mol Cell. 2003 Aug;12(2):509-16 [14536089.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6542-7 [15084747.001]
  • [Cites] Methods Mol Biol. 2004;287:99-120 [15273407.001]
  • [Cites] Nature. 2004 Aug 19;430(7002):857-64 [15318213.001]
  • [Cites] Genome Res. 2004 Sep;14(9):1696-703 [15342555.001]
  • [Cites] Immunogenetics. 2005 Jan;56(10):702-9 [15592824.001]
  • [Cites] J Hum Evol. 2005 Mar;48(3):237-57 [15737392.001]
  • [Cites] Nature. 2005 Apr 7;434(7034):724-31 [15815621.001]
  • [Cites] Curr Biol. 2006 Jan 24;16(2):119-29 [16431364.001]
  • [Cites] Trends Cell Biol. 2006 Feb;16(2):70-8 [16412639.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4186-91 [16537506.001]
  • [Cites] Genome Res. 2006 May;16(5):595-605 [16606705.001]
  • [Cites] Genome Biol. 2006;7(10):R91 [17040560.001]
  • [Cites] Science. 2007 Apr 13;316(5822):243-6 [17431171.001]
  • [Cites] Am J Hum Genet. 2008 Feb;82(2):261-82 [18252209.001]
  • [Cites] Chromosoma. 2008 Aug;117(4):339-44 [18274768.001]
  • [Cites] Genome Res. 2008 Sep;18(9):1530-7 [18552313.001]
  • [Cites] Genome Res. 2008 Dec;18(12):1875-83 [18836035.001]
  • [Cites] Genomics. 1991 Apr;9(4):770-4 [2037303.001]
  • (PMID = 19411601.001).
  • [ISSN] 1088-9051
  • [Journal-full-title] Genome research
  • [ISO-abbreviation] Genome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantigens; 0 / Chromosomal Proteins, Non-Histone; 0 / centromere protein A; 0 / centromere protein C
  • [Other-IDs] NLM/ PMC2675966
  •  go-up   go-down


47. Dranitzki-Elhalel M, Huang JH, Sasson M, Rachmilewitz J, Parnas M, Tykocinski ML: CD40.FasL inhibits human T cells: evidence for an auto-inhibitory loop-back mechanism. Int Immunol; 2007 Apr;19(4):355-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD40.FasL inhibits human T cells: evidence for an auto-inhibitory loop-back mechanism.
  • Taken together, these data are consistent with a 'loop-back' inhibitory mechanism within individual activated (CD40L and Fas receptor expressing) T cells causing suicide of these T cells.
  • [MeSH-minor] Animals. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / pharmacology. Antigens, CD3 / immunology. Antigens, CD8 / genetics. Antigens, CD8 / metabolism. Antigens, CD95 / metabolism. B-Lymphocytes / cytology. B-Lymphocytes / drug effects. B-Lymphocytes / metabolism. CD40 Ligand / genetics. CD40 Ligand / metabolism. Cell Line. Cell Line, Tumor. Cell Proliferation / drug effects. Coculture Techniques. Dose-Response Relationship, Drug. Humans. Jurkat Cells. Leukocytes, Mononuclear / cytology. Leukocytes, Mononuclear / drug effects. Leukocytes, Mononuclear / metabolism. Lymphocyte Activation / drug effects. Lymphocyte Activation / immunology. Mice. NIH 3T3 Cells. Protein Binding / drug effects. Transfection

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17314083.001).
  • [ISSN] 0953-8178
  • [Journal-full-title] International immunology
  • [ISO-abbreviation] Int. Immunol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI31044-11
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD3; 0 / Antigens, CD40; 0 / Antigens, CD8; 0 / Antigens, CD95; 0 / Fas Ligand Protein; 0 / Recombinant Fusion Proteins; 147205-72-9 / CD40 Ligand
  •  go-up   go-down


48. Radkevich-Brown O, Piechocki MP, Back JB, Weise AM, Pilon-Thomas S, Wei WZ: Intratumoral DNA electroporation induces anti-tumor immunity and tumor regression. Cancer Immunol Immunother; 2010 Mar;59(3):409-17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoral DNA electroporation induces anti-tumor immunity and tumor regression.
  • Transgene expression in the tumors was sustained for 2-3 weeks after intratumoral electroporation with mammalian expression plasmid containing firefly luciferase cDNA.
  • Intratumoral electroporation with TetC and IL-12 cDNA after mice were treated with CD25 mAb to remove regulatory T cells induced IFN-gamma producing T-cell response to tumor-associated antigen, heavy inflammatory infiltration, regression of established tumors and immune memory to protect mice from repeated tumor challenge.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2000 May;105(10):1383-93 [10811846.001]
  • [Cites] J Immunol. 2000 Nov 1;165(9):5133-42 [11046045.001]
  • [Cites] Vaccine. 2000 Nov 22;19(7-8):810-5 [11115703.001]
  • [Cites] J Clin Invest. 2001 Feb;107(4):477-84 [11181647.001]
  • [Cites] J Natl Cancer Inst Monogr. 2001;(30):96-102 [11773300.001]
  • [Cites] Mol Ther. 2002 Jun;5(6):668-75 [12027550.001]
  • [Cites] Nat Rev Immunol. 2003 Feb;3(2):133-46 [12563297.001]
  • [Cites] N Engl J Med. 2003 Aug 28;349(9):859-66 [12944571.001]
  • [Cites] Cancer Immunol Immunother. 2003 Oct;52(10):592-8 [12827305.001]
  • [Cites] J Clin Invest. 2004 Mar;113(5):664-7 [14991063.001]
  • [Cites] Immunol Rev. 2004 Jun;199:156-80 [15233733.001]
  • [Cites] J Biol Chem. 1977 Jan 10;252(1):187-93 [401808.001]
  • [Cites] J Leukoc Biol. 1985 Nov;38(5):573-85 [2413152.001]
  • [Cites] Eur J Immunol. 1989 Dec;19(12):2237-42 [2481588.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):21-6 [8548765.001]
  • [Cites] J Exp Med. 1998 Aug 3;188(3):589-96 [9687535.001]
  • [Cites] Int J Cancer. 1999 May 31;81(5):748-54 [10328228.001]
  • [Cites] Nat Rev Genet. 2005 Apr;6(4):299-310 [15761468.001]
  • [Cites] J Immunol. 2005 May 15;174(10):6292-8 [15879128.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8471-8 [16166327.001]
  • [Cites] Curr Gene Ther. 2006 Apr;6(2):243-73 [16611045.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):613-25 [16862192.001]
  • [Cites] Cell Immunol. 2006 Apr;240(2):96-106 [16930573.001]
  • [Cites] Cancer Gene Ther. 2006 Dec;13(12):1061-71 [16874363.001]
  • [Cites] J Immunol. 2007 Apr 1;178(7):4676-87 [17372027.001]
  • [Cites] Annu Rev Immunol. 2007;25:267-96 [17134371.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):7020-7 [17638915.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):7037-44 [17638917.001]
  • [Cites] J Immunol. 2007 Aug 1;179(3):1960-8 [17641063.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Mar;6(3):285-93 [18377847.001]
  • [Cites] BMC Cancer. 2008;8:120 [18439246.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7530-40 [18794141.001]
  • [Cites] Cancer Res. 2009 Jan 1;69(1):212-8 [19118005.001]
  • [Cites] Eur J Surg Oncol. 2009 Feb;35(2):113-22 [18502088.001]
  • [Cites] J Immunol. 2009 May 1;182(9):5873-81 [19380836.001]
  • [Cites] J Immunol. 2001 Sep 15;167(6):3367-74 [11544327.001]
  • (PMID = 19730859.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA076340; United States / NCI NIH HHS / CA / R01 CA125680; United States / NCI NIH HHS / CA / CA125680; United States / NCI NIH HHS / CA / CA76340
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Peptide Fragments; 0 / Tetanus Toxin; 0 / Vaccines, DNA; 0 / tetanus toxin fragment C; 187348-17-0 / Interleukin-12
  • [Other-IDs] NLM/ NIHMS486540; NLM/ PMC3702174
  •  go-up   go-down


49. Cohen SP, Wenzell D, Hurley RW, Kurihara C, Buckenmaier CC 3rd, Griffith S, Larkin TM, Dahl E, Morlando BJ: A double-blind, placebo-controlled, dose-response pilot study evaluating intradiscal etanercept in patients with chronic discogenic low back pain or lumbosacral radiculopathy. Anesthesiology; 2007 Jul;107(1):99-105
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A double-blind, placebo-controlled, dose-response pilot study evaluating intradiscal etanercept in patients with chronic discogenic low back pain or lumbosacral radiculopathy.
  • BACKGROUND: In recent years, convincing evidence has emerged implicating tumor necrosis factor alpha as a causative factor in radiculopathy and discogenic back pain.
  • But although preliminary open-label studies demonstrated promising results for the treatment of low back pain with tumor necrosis factor-alpha inhibitors, early optimism has been tainted by a controlled study showing no significant benefit in sciatica.
  • To determine whether outcomes might be improved by a more direct route of administration, the authors evaluated escalating doses of intradiscal etanercept in 36 patients with chronic lumbosacral radiculopathy or discogenic low back pain.
  • CONCLUSIONS: Although no serious side effects were observed in this small study, a single low dose of intradiscal etanercept does not seem to be an effective treatment for chronic radicular or discogenic low back pain.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Immunoglobulin G / administration & dosage. Immunoglobulin G / therapeutic use. Intervertebral Disc / pathology. Low Back Pain / drug therapy. Radiculopathy / drug therapy. Receptors, Tumor Necrosis Factor / administration & dosage. Receptors, Tumor Necrosis Factor / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Etanercept .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Anesthesiology. 2008 Feb;108(2):334; author reply 335 [18212586.001]
  • (PMID = 17585221.001).
  • [ISSN] 0003-3022
  • [Journal-full-title] Anesthesiology
  • [ISO-abbreviation] Anesthesiology
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; OP401G7OJC / Etanercept
  •  go-up   go-down


50. O'Brien M, Curtis C, D'Hemecourt P, Proctor M: Case report: a case of persistent back pain and constipation in a 5-year-old boy. Phys Sportsmed; 2009 Apr;37(1):133-7
MedlinePlus Health Information. consumer health - Constipation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: a case of persistent back pain and constipation in a 5-year-old boy.
  • Pediatric intramedullary spinal cord tumors are rare and account for 3% to 6% of all central nervous system tumors.
  • We report a case of an intramedullary spinal cord astrocytoma in a 5-year-old boy with nonspecific mid-back pain for 3 months.
  • An urgent magnetic resonance imaging showed an intramedullary tumor in the mid-thoracic cord, confirmed by surgical excision.
  • The physician should maintain a high index of suspicion when evaluating the pediatric patient who presents with unexplained and persistent back pain.
  • Associated findings, including nocturnal pain and neurological symptoms may indicate a more serious underlying pathology such as a tumor.
  • [MeSH-major] Astrocytoma / complications. Back Pain / etiology. Constipation / etiology. Spinal Cord Neoplasms / complications
  • [MeSH-minor] Child, Preschool. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Constipation.
  • MedlinePlus Health Information. consumer health - Back Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20048499.001).
  • [ISSN] 0091-3847
  • [Journal-full-title] The Physician and sportsmedicine
  • [ISO-abbreviation] Phys Sportsmed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Kuwada M, Hosokawa Y, Takada S, Kumamoto H, Hayashi Y, Fujimoto K, Hirao Y: [Adrenocortical carcinoma with intratumoral hemorrhage detected from chest and back pain: a case report]. Hinyokika Kiyo; 2009 Oct;55(10):599-602
MedlinePlus Health Information. consumer health - Chest Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adrenocortical carcinoma with intratumoral hemorrhage detected from chest and back pain: a case report].
  • A 55-year-old man visited our hospital with left chest and back pain.
  • Computed tomography (CT) showed left retroperitoneal tumor, which was 6 cm in diameter with intratumoral hemorrhage.
  • Based on abdominal CT, magnetic resonance imaging and blood tests, preoperative diagnosis was adrenocortical carcinoma.
  • En bloc resection of the tumor and the left kidney was performed.
  • The histological diagnosis was adrenocortical carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Back Pain / etiology. Carcinoma / diagnosis. Chest Pain / etiology. Hemorrhage / etiology

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • MedlinePlus Health Information. consumer health - Back Pain.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19926942.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


52. Foley DS, Sunil I, Debski R, Ignacio RC, Nagaraj HS: Primary hepatic carcinoid tumor in children. J Pediatr Surg; 2008 Nov;43(11):e25-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatic carcinoid tumor in children.
  • Primary carcinoid tumors of the liver are rare, with fewer than 60 cases currently reported in the English literature.
  • We present the evaluation and management of a solid hepatic tumor in a 14-year-old boy.
  • Final histopathologic evaluation of the mass revealed a carcinoid tumor.
  • Review of the literature suggests that primary hepatic carcinoid tumors are particularly rare in children.
  • As the liver is frequently a site for carcinoid metastasis from the gastrointestinal tract, any patient with a suspected primary hepatic carcinoid tumor must undergo an extensive search for an extrahepatic primary site.
  • These tumors are typically indolent but may metastasize.
  • In addition, medical therapy is of limited benefit in reducing tumor bulk.
  • The mainstay for treatment of primary hepatic carcinoid tumors is surgical resection, and these tumors carry a more favorable prognosis than other primary hepatic malignancies and metastatic carcinoid.
  • Follow-up is long-term, as these tumors can recur many years after initial resection.
  • [MeSH-major] Carcinoid Tumor / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Back Pain / etiology. Biomarkers, Tumor / blood. Chromogranin A / blood. Follow-Up Studies. Hematuria / etiology. Hepatectomy. Humans. Hydroxyindoleacetic Acid / blood. Incidental Findings. Magnetic Resonance Imaging. Male. Neoplasm Proteins / blood. Nephrolithiasis / complications. Nephrolithiasis / radiography. Prognosis. Tomography, X-Ray Computed. Vomiting / etiology. Weight Loss

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18970916.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Neoplasm Proteins; 54-16-0 / Hydroxyindoleacetic Acid
  •  go-up   go-down


53. Ozturk E, Erdem I, Sonmez G, Haholu A, Sildiroglu HO, Mutlu H, Basekim CC, Kizilkaya E: Multicentric malignant peripheral nerve sheath tumor. Clin Imaging; 2007 Sep-Oct;31(5):363-6
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric malignant peripheral nerve sheath tumor.
  • We present a case of malignant peripheral nerve sheath tumor of multicentric origin, an extremely rare condition.
  • A 25-year-old man was admitted to hospital with presenting symptoms of cough, dyspnea and left lateral back pain.
  • After surgical resection of the masses from the thoracic and inguinal regions, histological examination confirmed the preoperative diagnosis of malignant peripheral nerve sheath tumor.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Neoplasms, Multiple Primary / diagnosis. Nerve Sheath Neoplasms / diagnosis. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17825749.001).
  • [ISSN] 0899-7071
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Bernet A, Mehlen P: Dependence receptors: when apoptosis controls tumor progression. Bull Cancer; 2007 Apr;94(4):E12-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dependence receptors: when apoptosis controls tumor progression.
  • We have hypothesized that such a trait is a mechanism that allows inhibition of tumor growth, by inducing apoptosis "abnormal" cells that would usually grow in settings of ligand unavailability, i.e. local growth of tumor cells or growth beyond primary tumor site.
  • Along this line, back in the early 90s, Vogelstein and colleagues suggested that a gene called DCC (for deleted in colorectal cancer) could be a tumor suppressor gene because it was found to be deleted in more than 70% of colorectal cancers, as well as in many other cancers.
  • During the last fifteen years, controversial data have failed to firmly establish whether DCC is indeed a tumor suppressor gene.
  • However, our observation that DCC behaves as a dependence receptor that induces cell death unless its ligand netrin-1 is present, together with the fact that mice engineered to block DCC-induced cell death by overexpressing netrin-1 are predisposed to develop colorectal tumors, strengthen the role of dependence receptors as tumor suppressors.
  • In this review, we will describe the implication of the netrin-1/receptor pairs as novel negative regulators of tumor development.
  • [MeSH-major] Apoptosis / physiology. Colorectal Neoplasms / etiology. Nerve Growth Factors / physiology. Receptors, Cell Surface / physiology. Tumor Suppressor Proteins / physiology
  • [MeSH-minor] Animals. Cell Survival / physiology. Chromosomes, Human, Pair 18 / physiology. Genes, Tumor Suppressor / physiology. Humans. Mice

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17449433.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / DCC protein, human; 0 / Nerve Growth Factors; 0 / Receptors, Cell Surface; 0 / Tumor Suppressor Proteins; 0 / netrin receptors; 158651-98-0 / netrin-1
  •  go-up   go-down


55. Garg S, Dormans JP: Tumors and tumor-like conditions of the spine in children. J Am Acad Orthop Surg; 2005 Oct;13(6):372-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumors and tumor-like conditions of the spine in children.
  • Tumors and tumor-like conditions of the spine, although rare, should be included in the differential diagnosis of infants and children with back pain.
  • Skeletal pathology is more frequently the cause of back pain in children than in adults.
  • Although most tumors and tumor-like conditions of the spine in children are benign, many require surgery.
  • Children with malignant tumors of the spine (with the exception of leukemia and lymphoma) may require multimodality therapy, including surgery, to achieve long-term cure.
  • Advances in imaging, surgical technique, surgical technology, and adjuvant therapy have led to improvements in diagnosis and treatment and, thus, outcomes.
  • In many cases, however, early and accurate diagnosis is often possible based on only clinical history, physical examination, and plain radiographic imaging.
  • [MeSH-major] Spinal Cord Neoplasms / diagnosis. Spinal Cord Neoplasms / therapy. Spinal Neoplasms / diagnosis. Spinal Neoplasms / therapy
  • [MeSH-minor] Back Pain. Child. Child, Preschool. Combined Modality Therapy. Diagnosis, Differential. Diagnostic Imaging. Humans. Infant. Physical Examination

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16224110.001).
  • [ISSN] 1067-151X
  • [Journal-full-title] The Journal of the American Academy of Orthopaedic Surgeons
  • [ISO-abbreviation] J Am Acad Orthop Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


56. Huang YC, Tu DG, Wu JD, Lee MY: Malignant pleural mesothelioma presenting as low back pain: diagnosed by bone scan coordinating with F-18 FDG PET/CT. Spine (Phila Pa 1976); 2009 Oct 1;34(21):E780-3
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pleural mesothelioma presenting as low back pain: diagnosed by bone scan coordinating with F-18 FDG PET/CT.
  • OBJECTIVE: We report malignant pleural mesothelioma (MPM) discovered in a Tc-99m MDP bone scan as a photopenic lesion in a 64-year-old man presenting with low back pain and diagnosed with F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT).
  • SUMMARY OF BACKGROUND DATA: Malignant pleural mesothelioma, an uncommon neoplasm with a poor prognosis, arises from mesothelial cells of the pleura.
  • RESULTS: The Tc-99m MDP bone scan showed a photopenic defect occupying the left side of the T11 vertebra and implicated the existence of a tumor.
  • Pathologic analysis of the paraspinal tumor indicated metastatic neoplastic cells, which we initially suspected originated from the gastrointestinal tract.
  • CONCLUSION: The present case highlights both the value of a Tc-99m MDP bone scan when MPM presents, unusually, as low back pain, and the importance of carefully interpreting bone scan images, especially for photopenic defects.
  • It also indicates the usefulness of F-18 FDG PET/CT study in MPM in a difficult histopathological diagnosis.
  • [MeSH-major] Low Back Pain / etiology. Mesothelioma / complications. Mesothelioma / diagnosis. Pleural Neoplasms / complications. Pleural Neoplasms / diagnosis. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19934799.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


57. Pellicciari R, Gioiello A, Costantino G, Sadeghpour BM, Rizzo G, Meyer U, Parks DJ, Entrena-Guadix A, Fiorucci S: Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives. J Med Chem; 2006 Jul 13;49(14):4208-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.
  • Carbamate derivatives of bile acids were synthesized with the aim of systematically exploring the potential for farnesoid X receptor (FXR) modulation endowed with occupancy of the receptor's back door, localized between loops H1-H2 and H4-H5.
  • Docking studies clearly indicate that the side chain of the new derivatives fits in a so far unexploited receptor cavity localized near the "back door" of FXR.
  • [MeSH-minor] Cell Line, Tumor. Drug Design. Fluorescence Resonance Energy Transfer. Genes, Reporter. Histone Acetyltransferases. Humans. Ligands. Luciferases / genetics. Models, Molecular. Nuclear Receptor Coactivator 1. Receptors, Cytoplasmic and Nuclear. Receptors, Steroid / metabolism. Response Elements. Structure-Activity Relationship. Transfection

  • COS Scholar Universe. author profiles.
  • BindingDB. BindingDB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16821780.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Ligands; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Receptors, Steroid; 0 / Transcription Factors; 0 / farnesoid X-activated receptor; 0GEI24LG0J / Chenodeoxycholic Acid; EC 1.13.12.- / Luciferases; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / NCOA1 protein, human; EC 2.3.1.48 / Nuclear Receptor Coactivator 1
  •  go-up   go-down


58. Kim BS, Shin JH, Moon HS, Chon JY, Sung CH: Post-traumatic Back Pain Revealed as Tuberculous Spondylitis -A Case Report-. Korean J Pain; 2010 Mar;23(1):74-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-traumatic Back Pain Revealed as Tuberculous Spondylitis -A Case Report-.
  • Tuberculous spondylitis is a very rare disease, but it can result in bone destruction, kyphotic deformity, spinal instability, and neurologic complications unless early diagnosis and proper management are done.
  • Because the most common symptom of tuberculous spondylitis is back pain, it can often be misdiagnosed.
  • Atypical tuberculous spondylitis can be presented as a metastatic cancer or a primary vertebral tumor.
  • We must make a differential diagnosis through adequate biopsy.
  • A 30-year-old man visited our clinic due to back and chest pain after a recent traffic accident.
  • Finally, we confirmed tuberculous spondylitis diagnosis with the biopsy results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurochir (Wien). 1987;88(1-2):26-33 [3425410.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):243-7 [7616269.001]
  • [Cites] Radiology. 1993 Nov;189(2):489-93 [8210378.001]
  • [Cites] Intern Med. 1996 Nov;35(11):883-5 [8968802.001]
  • [Cites] J Korean Med Sci. 2009 Apr;24(2):237-41 [19399264.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Feb 15;167(4):603-62 [12588714.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Jun 15;171(12):1430-5 [15831840.001]
  • [Cites] J Clin Rheumatol. 2005 Feb;11(1):17-20 [16357692.001]
  • [Cites] Ann Intern Med. 1997 Feb 1;126(3):237-43 [9027277.001]
  • (PMID = 20552079.001).
  • [ISSN] 2093-0569
  • [Journal-full-title] The Korean journal of pain
  • [ISO-abbreviation] Korean J Pain
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2884205
  • [Keywords] NOTNLM ; back pain / biopsy / differential diagnosis / tuberculous spondylitis
  •  go-up   go-down


59. Liu YJ, Wang GM, Zhang YK, Zhang L, Sun LA, Lin ZM, Zhu TY: [The clinical characteristic of adrenal metastatic tumor]. Zhonghua Wai Ke Za Zhi; 2007 Jan 15;45(2):124-7
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical characteristic of adrenal metastatic tumor].
  • RESULTS: Lung and hepatocellular carcinoma were the most common primary tumor of adrenal metastatic tumor, which about 36.9% (38/103) and 42.7% (44/103) of all cases, followed by renal carcinoma 6.8% (7/103), colorectal carcinoma 4.9% (5/103), stomach carcinoma 3.9% (4/103), breast cancer 1.9% (2/103), unknown primary tumor 2.9% (3/103).
  • The mean interval from detection of primary tumor to adrenal metastasis was 9.5 months.
  • Only 5 cases (4.9%) were presented with pain in the back.
  • CONCLUSIONS: There is no particular presentation of clinic and imaging, diagnosis depending on history, follow-up and the pathological presentation of primary tumor.
  • When the primary tumor could be resected or be well controlled, and there is no other evidence of metastasis, adrenalectomy is recommended.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17418043.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


60. Mendiratta-Lala M, Kader Ellika S, Gutierrez JA, Patel SC, Jain R: Spinal cord pilomyxoid astrocytoma: an unusual tumor. J Neuroimaging; 2007 Oct;17(4):371-4
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal cord pilomyxoid astrocytoma: an unusual tumor.
  • We present the imaging findings of a case of spinal pilomyxoid astrocytoma in a 29-year-old woman with history of neck and back pain and weakness of bilateral upper extremities.
  • This report illustrates the MR findings of an unusual case of intradural extramedullary spinal pilomyxoid tumor in an adult patient.
  • [MeSH-major] Astrocytoma / diagnosis. Magnetic Resonance Imaging. Myxoma / diagnosis. Spinal Cord Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17894633.001).
  • [ISSN] 1051-2284
  • [Journal-full-title] Journal of neuroimaging : official journal of the American Society of Neuroimaging
  • [ISO-abbreviation] J Neuroimaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


61. Jeong IH, Lee JK, Moon KS, Kwak HJ, Joo SP, Kim TS, Kim JH, Kim SH: Iatrogenic intraspinal epidermoid tumor: case report. Pediatr Neurosurg; 2006;42(6):395-8
MedlinePlus Health Information. consumer health - Spinal Cord Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iatrogenic intraspinal epidermoid tumor: case report.
  • Iatrogenic spinal epidermoid tumors are extremely rare and may be caused by skin fragments which were implanted in the spine as a result of a trauma or lumbar puncture.
  • Due to the time lag between the lumbar puncture and the development of a symptomatic tumor, this relationship is often overlooked and can cause a delay in the proper diagnosis.
  • Here, we report a rare case of an intraspinal epidermoid tumor, which developed 7 years after a lumbar puncture in a 12-year-old boy, who presented with back pain and radiating pain to the posterior of both thighs.
  • A total excision of the tumor via L3-L4 hemilaminectomy yielded a good functional recovery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 17047423.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


62. Amrolia PJ, Mucioli-Casadei G, Huls H, Heslop HE, Schindler J, Veys P, Vitetta ES, Brenner MK: Add-back of allodepleted donor T cells to improve immune reconstitution after haplo-identical stem cell transplantation. Cytotherapy; 2005;7(2):116-25
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Add-back of allodepleted donor T cells to improve immune reconstitution after haplo-identical stem cell transplantation.
  • We have shown that using recipient EBV-transformed LCL as stimulators to activate donor alloreactive T cells results in more consistent depletion of in vitro alloreactivity while preserving T-cell responses to viral and potential myeloid tumor Ag.
  • Based on these data, we have embarked on a phase I clinical dose escalation study of add-back of allo-LCL-depleted donor T cells in the haplo-identical setting, to determine if the allodepletion we achieve to allow infusion of sufficient T cells to restore useful antiviral/anti-leukemic responses without causing GvHD.

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16047416.001).
  • [ISSN] 1465-3249
  • [Journal-full-title] Cytotherapy
  • [ISO-abbreviation] Cytotherapy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 12
  •  go-up   go-down


63. Funahashi Y, Hattori R, Yamamoto T, Mizutani K, Yoshino Y, Matsukawa Y, Sassa N, Okumura K, Gotoh M: Ewing's sarcoma / primitive neuroectodermal tumor of the kidney. Aktuelle Urol; 2009 Aug;40(4):247-9
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewing's sarcoma / primitive neuroectodermal tumor of the kidney.
  • A 42-year-old female presented with right back pain.
  • The histopathological examination revealed a high-grade primitive small round tumor the cells of which were strongly positive for CD99 and vimentin.
  • The diagnosis was Ewing's sarcoma / primitive neuroectodermal tumor of the kidney.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Neuroectodermal Tumors, Primitive / diagnosis. Sarcoma, Ewing / diagnosis
  • [MeSH-minor] Adult. Biomarkers, Tumor / genetics. Calmodulin-Binding Proteins / genetics. Chemotherapy, Adjuvant. Chromosomes, Human, Pair 22 / genetics. Combined Modality Therapy. Diagnosis, Differential. Disease-Free Survival. Female. Gene Rearrangement / genetics. Humans. In Situ Hybridization, Fluorescence. Kidney / pathology. Laparoscopy. Lymph Node Excision. Nephrectomy. RNA-Binding Proteins / genetics. Radionuclide Imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19294616.001).
  • [ISSN] 1438-8820
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calmodulin-Binding Proteins; 0 / EWSR1 protein, human; 0 / RNA-Binding Proteins
  •  go-up   go-down


64. Harrington LS, Findlay GM, Lamb RF: Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci; 2005 Jan;30(1):35-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Restraining PI3K: mTOR signalling goes back to the membrane.
  • [MeSH-minor] Animals. Diabetes Mellitus, Type 2 / genetics. Diabetes Mellitus, Type 2 / metabolism. Diabetes Mellitus, Type 2 / pathology. Glucose / metabolism. Humans. Insulin / physiology. PTEN Phosphohydrolase. Phosphatidylinositol Phosphates / metabolism. Phosphoric Monoester Hydrolases / genetics. Phosphoric Monoester Hydrolases / metabolism. Somatomedins / physiology. TOR Serine-Threonine Kinases. Tuberous Sclerosis / genetics. Tuberous Sclerosis / metabolism. Tuberous Sclerosis / pathology. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism

  • Hazardous Substances Data Bank. GLUCOSE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15653324.001).
  • [ISSN] 0968-0004
  • [Journal-full-title] Trends in biochemical sciences
  • [ISO-abbreviation] Trends Biochem. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Insulin; 0 / Phosphatidylinositol Phosphates; 0 / Somatomedins; 0 / Tumor Suppressor Proteins; 0 / phosphatidylinositol 3,4,5-triphosphate; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; IY9XDZ35W2 / Glucose
  • [Number-of-references] 80
  •  go-up   go-down


65. Dubois JB: [Intraoperative radiotherapy: back to the future?]. Cancer Radiother; 2009 Sep;13(5):423-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraoperative radiotherapy: back to the future?].
  • [Transliterated title] Quel avenir pour la radiothérapie peropératoire ?
  • The main goal was to increase the total dose in a limited volume leading to an optimized therapeutic ratio between the tumor and the healthy tissue.
  • The main indications are not only recurrences of digestive and gynecological tumors but also retroperitoneal sarcomas.
  • Recently, the development of the concept of partial breast irradiation reinforces the use of such a technique in the strategy of breast-conserving surgery for small tumors in the elderly.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19640763.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 27
  •  go-up   go-down


66. Duda DG: Antiangiogenesis and drug delivery to tumors: bench to bedside and back. Cancer Res; 2006 Apr 15;66(8):3967-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiangiogenesis and drug delivery to tumors: bench to bedside and back.
  • Because these advances have come primarily with the use of combinations of antiangiogenic agents with chemotherapy, or with antiangiogenic agents that also directly target the cancer cells, the central theme included the issue of drug delivery to tumors.
  • This resulted in an excellent overview of the advances in our understanding of cellular and molecular aspects of tumor angiogenesis and antiangiogenic therapy of cancer in combination with conventional therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618712.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors
  •  go-up   go-down


67. Kiatsoontorn K, Takami T, Ichinose T, Chokyu I, Tsuyuguchi N, Ohsawa M, Ohata K: Primary epidural peripheral primitive neuroectodermal tumor of the thoracic spine. Neurol Med Chir (Tokyo); 2009 Nov;49(11):542-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary epidural peripheral primitive neuroectodermal tumor of the thoracic spine.
  • A 25-year-old male patient presented with an extremely rare primary spinal peripheral primitive neuroectodermal tumor (pPNET) manifesting as acutely progressive paraparesis and back pain.
  • Neuroimaging and intraoperative examination showed that the tumor was confined to the epidural space of the thoracic spine.
  • The patient was treated successfully by gross total resection of the tumor followed by chemotherapy and local radiotherapy.
  • The present case illustrates the unexpected occurrence and important differential diagnosis of primary epidural pPNET of the thoracic spine in young patients presenting with progressive paraparesis and back pain.
  • [MeSH-major] Epidural Space / pathology. Neuroectodermal Tumors, Primitive / pathology. Spinal Canal / pathology. Spinal Cord Compression / pathology. Spinal Neoplasms / pathology. Thoracic Vertebrae / pathology
  • [MeSH-minor] Adult. Back Pain / etiology. Combined Modality Therapy / methods. Combined Modality Therapy / standards. Decompression, Surgical. Diagnosis, Differential. Disease Progression. Drug Therapy / methods. Dura Mater / pathology. Dura Mater / surgery. Humans. Laminectomy. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. Paraparesis / etiology. Radiotherapy / methods. Spinal Cord / pathology. Spinal Cord / radiography. Spinal Cord / surgery. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19940407.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


68. Oku H, Li C, Shimatani M, Iwasaki H, Toda T, Okabe T, Watanabe H: Tumor specific cytotoxicity of beta-glucosylceramide: structure-cytotoxicity relationship and anti-tumor activity in vivo. Cancer Chemother Pharmacol; 2009 Aug;64(3):485-96
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor specific cytotoxicity of beta-glucosylceramide: structure-cytotoxicity relationship and anti-tumor activity in vivo.
  • Unglycosylated ceramide had no selective cytotoxicity which demonstrated that the sugar moiety plays a critical role for the expression of selective cytotoxicity by beta-GluCer. beta-Galactosylceramide also showed tumor specific cytotoxicity suggesting that the chemical structure of sugar group is not a factor for the selective toxicity.
  • Intraperitoneal administration of beta-GluCer significantly suppressed the growth of tumor implanted to the back of mice. beta-GluCer also induced antitumor immunity via the activation of NKT cells in vivo, and decreased the tumor metastasis of lymphoma cells.
  • [MeSH-minor] Animals. Cell Cycle / drug effects. Cell Line, Tumor. Drug Screening Assays, Antitumor. Humans. Hydrophobic and Hydrophilic Interactions. Injections, Intraperitoneal. Male. Mice. Mice, Inbred C3H. Mice, Inbred C57BL. Natural Killer T-Cells / drug effects. Natural Killer T-Cells / metabolism. Necrosis / pathology. Neoplasm Metastasis / drug therapy. Neoplasm Transplantation. Reactive Oxygen Species / metabolism. Structure-Activity Relationship

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19104811.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucosylceramides; 0 / Reactive Oxygen Species
  •  go-up   go-down


69. André N, Padovani L, Verschuur A: Metronomic chemotherapy: Back to the future! Drug News Perspect; 2010 Mar;23(2):143-51
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metronomic chemotherapy: Back to the future!
  • It is thought to work primarily through antiangiogenic mechanisms and has the property to kill resistant cancer cells and/or to inhibit tumor growth while significantly reducing undesirable toxic side effects.
  • [MeSH-minor] Animals. Drug Administration Schedule. Drug Delivery Systems. Drug Resistance, Neoplasm. Humans. Neovascularization, Pathologic / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Prous Science, S.A.U. or its licensors. All rights reserved.
  • (PMID = 20369080.001).
  • [ISSN] 0214-0934
  • [Journal-full-title] Drug news & perspectives
  • [ISO-abbreviation] Drug News Perspect.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents
  • [Number-of-references] 93
  •  go-up   go-down


70. Waldmann A, Lautz E, Hampe J, Schreiber S, Schafmayer C, Katalinic A: [Utilization of inpatient rehabilitation of younger patients with colorectal neoplasms--results of the project "Popgen-colorectal cancer"]. Rehabilitation (Stuttg); 2007 Dec;46(6):349-55
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Popgen-Darmkrebs: Reha-Inanspruchnahme von jüngeren Patienten mit kolorektalem Tumor.
  • At time of diagnosis women are 5 years older than men (median: 73 vs. 68 years).
  • For this project younger patients (<65 yrs) with colorectal neoplasms (ICD-10 diagnosis C18-C21) who where living in Schleswig-Holstein and who had received the diagnosis between Jan.
  • RESULTS: In all, 245 patients participated and sent back the questionnaire (37+/-15 months after receiving the primary diagnosis).
  • [MeSH-minor] Colostomy / rehabilitation. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Marital Status. Middle Aged. Neoplasm Staging. Patient Acceptance of Health Care. Socioeconomic Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18188806.001).
  • [ISSN] 0034-3536
  • [Journal-full-title] Die Rehabilitation
  • [ISO-abbreviation] Rehabilitation (Stuttg)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


71. Mobley BC, Roulston D, Shah GV, Bijwaard KE, McKeever PE: Peripheral primitive neuroectodermal tumor/Ewing's sarcoma of the craniospinal vault: case reports and review. Hum Pathol; 2006 Jul;37(7):845-53
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral primitive neuroectodermal tumor/Ewing's sarcoma of the craniospinal vault: case reports and review.
  • The peripheral primitive neuroectodermal tumor/Ewing's sarcoma family tumor (pPNET/ESFT) group includes small round cell tumors of the bone, soft tissue, and nerve with morphological attributes of the germinal neuroepithelium.
  • An intradural tumor arising from the nerve roots of the cauda equina was discovered in a 32-year-old man presenting with radiculopathic back pain and lower-extremity weakness.
  • [MeSH-major] Brain Neoplasms / pathology. Cauda Equina / pathology. Neuroectodermal Tumors, Primitive, Peripheral / pathology. Peripheral Nervous System Neoplasms / pathology. Sarcoma, Ewing / pathology
  • [MeSH-minor] Adult. Antigens, CD / metabolism. Back Pain / etiology. Blotting, Southern. Cell Adhesion Molecules / metabolism. Chromosome Aberrations. Chromosomes, Human, Pair 22 / genetics. Diagnosis, Differential. Headache / etiology. Humans. Male. Meningioma / pathology. Oncogene Proteins, Fusion / genetics. Proto-Oncogene Protein c-fli-1 / genetics. RNA-Binding Protein EWS. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784984.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / EWS-FLI fusion protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Protein c-fli-1; 0 / RNA-Binding Protein EWS
  • [Number-of-references] 68
  •  go-up   go-down


72. Al Akloby O, Bukhari IA, El-Shawarby M, Al Mulhim F: Malignant peripheral nerve sheath tumor of the skin: case report. Am J Clin Dermatol; 2006;7(3):201-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumor of the skin: case report.
  • Malignant peripheral nerve sheath tumors (MPNSTs) are rare tumors derived from Schwann cells or pluripotent cells of the neural crest.
  • In this report, we describe a 21-year-old Saudi woman who presented with an asymptomatic, solid, round, protruding tumor on the right upper back which was diagnosed as an MPNST with no stigmata of neurofibromatosis.
  • [MeSH-major] Nerve Sheath Neoplasms / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Back. Female. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16734508.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] New Zealand
  •  go-up   go-down


73. Yang C, Ma J, Yang X, Jia L, Liu H, Xiao J: Natural killer/T-cell nasal-type lymphoma: unusual primary spinal tumor. Spine (Phila Pa 1976); 2008 Nov 15;33(24):E929-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural killer/T-cell nasal-type lymphoma: unusual primary spinal tumor.
  • OBJECTIVE: To describe the presentation and diagnosis of this disorder along with an emphasis on the importance of this type of rare tumor, needing early and accurate immunophenotypic profiling to make a right diagnosis.
  • It usually originates in the nasal cavity/nasopharynx and invades the surrounding tissues, which is aggressive and, usually, a delay in diagnosis could result in a fatal outcome.
  • METHODS: A 60-year-old man presented with severe pain in his chest and back for 3 weeks and developed paralysis soon.
  • The unfavorable prognosis of this tumor emphasized the need for novel molecular targets and more effective therapies.
  • [MeSH-minor] Back Pain / etiology. Back Pain / pathology. Chest Pain / etiology. Chest Pain / pathology. Fatal Outcome. Humans. Immunophenotyping. Joint Instability / etiology. Joint Instability / pathology. Magnetic Resonance Imaging. Male. Middle Aged. Multiple Organ Failure / etiology. Multiple Organ Failure / pathology. Paralysis / etiology. Severity of Illness Index. Spinal Cord Compression / etiology. Spinal Cord Compression / pathology. Spinal Fractures / etiology. Spinal Fractures / pathology. Spinal Fusion. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011534.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


74. Hashimoto N, Hakamada K, Narumi S, Totsuka E, Aoki K, Kamata Y, Sasaki M: Heterotopic gastrointestinal mucosa and pancreatic tissue in a retroperitoneal tumor. J Hepatobiliary Pancreat Surg; 2006;13(4):351-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterotopic gastrointestinal mucosa and pancreatic tissue in a retroperitoneal tumor.
  • We believe that this is the first report of a retroperitoneal tumor consisting of heterotopic gastrointestinal mucosa and pancreatic tissue.
  • The patient was a 19-year-old woman with the chief complaint being occasional back pain.
  • Angiography revealed that the inferior vena cava was displaced by the hypovascular tumor.
  • The retroperitoneal lesion was diagnosed preoperatively as a benign tumor such as a neurogenic neoplasm or lymphangioma.
  • At laparotomy, a cystic tumor was found, which existed behind the inferior vena cava and renal vessels, and contained reddish-brown fluid, suggesting hemorrhage in the past.
  • The cut surface of the tumor showed a unilocular cyst with partially hypertrophic wall.
  • Histopathological examination revealed a cystic tumor lined with heterotopic gastric and duodenal mucosa, with pancreatic tissue in the muscularis propria.
  • In addition, evidence of bleeding from the gastric mucosa was observed in the cystic tumor.
  • External secretion from these tissues could have triggered the hemorrhage and expanded the tumor, possibly resulting in the back pain.
  • [MeSH-major] Back Pain / etiology. Choristoma / pathology. Gastric Mucosa. Intestinal Mucosa. Retroperitoneal Neoplasms / pathology. Vascular Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Back Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16858549.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


75. Min KW, Seo IS, Pitha J: Ossifying fibromyxoid tumor: modified myoepithelial cell tumor? Report of three cases with immunohistochemical and electron microscopic studies. Ultrastruct Pathol; 2005 Nov-Dec;29(6):535-48
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ossifying fibromyxoid tumor: modified myoepithelial cell tumor? Report of three cases with immunohistochemical and electron microscopic studies.
  • Ossifying fibromyxoid tumors (OFMT) are rare soft tissue tumors of uncertain histogenesis and clinical behavior.
  • Three examples of soft tissue tumors with typical histopathologic characteristics of OFMT were studied: case 1, a 43-year-old female with a 2.5-cm tumor of the back; case 2, a 56-year-old man with an 8-cm thigh mass; and case 3, an 81-year-old female with a 13.5-cm buttock tumor.
  • Immunohistochemistry showed that the tumor cells were positive for vimentin and S-100 protein in all 3 cases.
  • By electron microscopy, tumor cells were characterized by centrally located round to oval nuclei with varying amounts of cytoplasm containing scanty cytoplasmic organelles.
  • In case 3, which behaved as a malignant tumor, the tumor cells were less differentiated spindle cells with primitive cellular features, and EL was rarely found along the short span of tumor cell borders.
  • In this study, tumor cells in OFMT were polygonal to stellate often with multiple short cytoplasmic processes.
  • The tumor cells were found to form cell clusters attached by primitive intercellular junctions between cytoplasmic processes forming intercellular bridges.
  • These ultrastructural findings together with immunophenotypic expression of S-100 protein presented closer resemblance to those of modified myoepithelial cells in pleomorphic adenomas of salivary glands and skin appendages rather than peripheral nerve sheath tumors.
  • They also conclude that ultrastructural study not only helps accurate diagnosis, but also may aid in predicting malignant behavior by the degree of deviation from the typical examples of OFMT.
  • [MeSH-minor] Adult. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Male. Microscopy, Electron, Transmission. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16316954.001).
  • [ISSN] 0191-3123
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


76. Abdulazim A, Citak M, Backhaus M, Stienen MN, Horch C: Primary carcinoid tumor of the filum terminale--a case report. Acta Neurochir (Wien); 2010 Nov;152(11):1975-9
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinoid tumor of the filum terminale--a case report.
  • Carcinoid tumors with a primary site in the central nervous system have not been reported in literature yet.
  • We report here about a 41-year-old patient with recurrent and progressive low back pain and bilateral S1 radiculopathy on admission.
  • The patient underwent hemi-laminectomies of the vertebral bodies L5 and S1 and an en bloc resection of the tumor.
  • Postoperative histopathological examination resulted in a well-differentiated intrathecal neuroendocrine tumor (carcinoid) of the terminal filum.
  • Postoperative staging showed no pathological abnormalities and no tumor recurrence after 6 months.
  • Even though rare, carcinoids should be considered as differential diagnosis of tumors occurring in the CNS.
  • [MeSH-major] Carcinoid Tumor / pathology. Cauda Equina / pathology. Low Back Pain / etiology. Radiculopathy / etiology. Spinal Cord Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676702.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


77. Wadhwa RK, Shaya MR, Nanda A: Spinal cord compression in a patient with a pain pump for failed back syndrome: a chalk-like precipitate mimicking a spinal cord neoplasm: case report. Neurosurgery; 2006 Feb;58(2):E387; discussion E387
Hazardous Substances Data Bank. CALCIUM CARBONATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal cord compression in a patient with a pain pump for failed back syndrome: a chalk-like precipitate mimicking a spinal cord neoplasm: case report.
  • CLINICAL PRESENTATION: We report the case of a 67-year-old female patient with failed back syndrome who presented with sensory complaints and back pain.
  • The mass was originally thought to be a spinal cord tumor; however, operation and chemical analysis of the mass showed that it was a bupivacaine precipitate at the tip of the catheter of the pain pump.
  • CONCLUSION: This is the first such case, to our knowledge, of a bupivacaine precipitate mimicking a spinal cord tumor.
  • [MeSH-minor] Aged. Back Pain / drug therapy. Back Pain / radiography. Bupivacaine / administration & dosage. Diagnosis, Differential. Female. Humans. Syndrome

  • Genetic Alliance. consumer health - Spinal cord neoplasm.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462469.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] H0G9379FGK / Calcium Carbonate; Y8335394RO / Bupivacaine
  •  go-up   go-down


78. Cai X, Gray PJ Jr, Von Hoff DD: DNA minor groove binders: back in the groove. Cancer Treat Rev; 2009 Aug;35(5):437-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA minor groove binders: back in the groove.
  • These agents have demonstrable anti-tumor activity against a wide variety of tumor types including leukemias, sarcomas, melanomas, breast and ovarian cancers.
  • Applying these agents according to a particular tumor's context of vulnerability might reveal previously unconsidered applications for this diverse class of agents.
  • This review provides a look at how minor groove binding agents have progressed from the lab through the clinic with particular emphasis on identifying the contexts of vulnerabilities of patient tumors which increase the effectiveness of these drugs.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19328629.001).
  • [ISSN] 1532-1967
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 9007-49-2 / DNA
  • [Number-of-references] 97
  •  go-up   go-down


79. Love RR, Uy GB: Surgical oophorectomy for breast cancer: back to the future. Future Oncol; 2008 Dec;4(6):785-92
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical oophorectomy for breast cancer: back to the future.
  • Greater understanding of the critical variables in pathology procedures for breast tumor tissue hormonal receptor testing is leading to better definitions of the specific patients for whom hormonal therapies are indicated.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19086845.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 44
  •  go-up   go-down


80. Walker LS: Regulatory T cells overturned: the effectors fight back. Immunology; 2009 Apr;126(4):466-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulatory T cells overturned: the effectors fight back.
  • These include Toll-like receptor (TLR) signals, cytokines [in particular those that use the common gamma chain, such as interleukin (IL)-7 and IL-21] and the triggering of tumour necrosis factor (TNF) receptor family members (such as glucocorticoid induced tumor necrosis factor receptor (GITR), OX40 and 4-1BB).
  • [MeSH-minor] Autoimmunity / immunology. Cytokines / immunology. Humans. Immune Tolerance / immunology. Infection / immunology. Models, Immunological. Receptors, Tumor Necrosis Factor / immunology. Signal Transduction / immunology. Toll-Like Receptors / immunology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2005 Jan 17;201(2):181-7 [15657288.001]
  • [Cites] Int Immunol. 2005 Mar;17(3):279-88 [15684039.001]
  • [Cites] Arthritis Rheum. 2005 Apr;52(4):1180-4 [15818683.001]
  • [Cites] Diabetes. 2005 May;54(5):1415-22 [15855328.001]
  • [Cites] J Exp Med. 2005 Jun 6;201(11):1793-803 [15939793.001]
  • [Cites] J Immunol. 2005 Jun 15;174(12):7645-53 [15944265.001]
  • [Cites] J Immunol. 2005 Jul 15;175(2):641-5 [16002658.001]
  • [Cites] J Immunol. 2005 Sep 1;175(5):3025-32 [16116190.001]
  • [Cites] Science. 2005 Aug 26;309(5739):1380-4 [16123302.001]
  • [Cites] J Immunol. 2005 Oct 1;175(7):4180-3 [16177055.001]
  • [Cites] J Immunol. 2005 Oct 1;175(7):4255-64 [16177065.001]
  • [Cites] J Exp Med. 2005 Oct 17;202(8):1075-85 [16230475.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1142-51 [16227984.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10878-83 [12949259.001]
  • [Cites] J Immunol. 2003 Oct 15;171(8):4040-7 [14530324.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15059-64 [14608036.001]
  • [Cites] J Immunol. 2004 Mar 15;172(6):3580-9 [15004159.001]
  • [Cites] Immunology. 2004 Feb;111(2):129-37 [15027897.001]
  • [Cites] Cell. 2004 Apr 16;117(2):265-77 [15084263.001]
  • [Cites] J Leukoc Biol. 2004 May;75(5):785-91 [14694186.001]
  • [Cites] J Immunol. 2004 May 15;172(10):5823-7 [15128759.001]
  • [Cites] J Immunol. 2004 Jun 1;172(11):6519-23 [15153463.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):1059-65 [15240694.001]
  • [Cites] J Exp Med. 2004 Aug 2;200(3):277-85 [15280421.001]
  • [Cites] J Immunol. 2004 Aug 15;173(4):2428-34 [15294956.001]
  • [Cites] J Immunol. 2004 Oct 15;173(8):5008-20 [15470044.001]
  • [Cites] J Immunol. 1999 May 1;162(9):5317-26 [10228007.001]
  • [Cites] J Immunol. 2004 Dec 15;173(12):7249-58 [15585847.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1071-2 [16239920.001]
  • [Cites] J Immunol. 2005 Dec 15;175(12):8051-9 [16339542.001]
  • [Cites] J Clin Invest. 2006 Feb;116(2):485-94 [16424940.001]
  • [Cites] J Immunol. 2006 Apr 1;176(7):3900-4 [16547222.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7048-53 [16632602.001]
  • [Cites] J Immunol. 2006 Jun 15;176(12):7278-87 [16751371.001]
  • [Cites] Blood. 2006 Jul 1;108(1):253-61 [16537805.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):2022-32 [16767222.001]
  • [Cites] Clin Immunol. 2006 Aug;120(2):121-8 [16766227.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2501-10 [17575071.001]
  • [Cites] J Immunol. 2007 Dec 1;179(11):7295-304 [18025172.001]
  • [Cites] Nat Immunol. 2007 Dec;8(12):1353-62 [17982458.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19446-51 [18042719.001]
  • [Cites] Oncogene. 2008 Jan 7;27(2):168-80 [18176598.001]
  • [Cites] J Immunol. 2008 Feb 15;180(4):2496-503 [18250459.001]
  • [Cites] J Immunol. 2008 Apr 15;180(8):5393-401 [18390721.001]
  • [Cites] J Exp Med. 2008 Apr 14;205(4):825-39 [18362171.001]
  • [Cites] Lupus. 2008 Apr;17(4):289-94 [18413409.001]
  • [Cites] Immunology. 2008 May;124(1):13-22 [18346152.001]
  • [Cites] Nat Rev Immunol. 2008 Jul;8(7):523-32 [18566595.001]
  • [Cites] Arthritis Rheum. 2008 Jul;58(7):2120-30 [18576316.001]
  • [Cites] J Immunol. 2008 Aug 1;181(3):1683-91 [18641304.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10113-8 [18635688.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14028-33 [18779574.001]
  • [Cites] Science. 2008 Oct 10;322(5899):271-5 [18845758.001]
  • [Cites] J Immunol. 2009 Jan 1;182(1):274-82 [19109158.001]
  • [Cites] J Immunol. 2000 Jan 1;164(1):183-90 [10605010.001]
  • [Cites] Nature. 2000 Jan 13;403(6766):211-6 [10646608.001]
  • [Cites] Eur J Immunol. 2000 Jun;30(6):1538-43 [10898488.001]
  • [Cites] J Exp Med. 2000 Jul 17;192(2):295-302 [10899916.001]
  • [Cites] J Exp Med. 2000 Jul 17;192(2):303-10 [10899917.001]
  • [Cites] Nat Genet. 2001 Jan;27(1):68-73 [11138001.001]
  • [Cites] J Exp Med. 2001 Jun 4;193(11):1303-10 [11390437.001]
  • [Cites] J Immunol. 2001 Aug 1;167(3):1137-40 [11466326.001]
  • [Cites] Nat Immunol. 2001 Sep;2(9):870-5 [11526404.001]
  • [Cites] Nat Immunol. 2002 Jan;3(1):48-54 [11740499.001]
  • [Cites] Nat Immunol. 2002 Feb;3(2):135-42 [11812990.001]
  • [Cites] J Cell Sci. 2002 Feb 15;115(Pt 4):679-88 [11865024.001]
  • [Cites] Immunity. 2002 Feb;16(2):311-23 [11869690.001]
  • [Cites] J Immunol. 2002 Dec 1;169(11):6210-7 [12444126.001]
  • [Cites] J Immunol. 2003 Jan 1;170(1):394-9 [12496424.001]
  • [Cites] J Exp Med. 2003 Jan 6;197(1):111-9 [12515818.001]
  • [Cites] Science. 2003 Feb 14;299(5609):1033-6 [12532024.001]
  • [Cites] J Exp Med. 2003 Feb 17;197(4):403-11 [12591899.001]
  • [Cites] Eur J Immunol. 2003 Feb;33(2):502-11 [12645949.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):330-6 [12612578.001]
  • [Cites] J Exp Med. 2003 Jul 21;198(2):235-47 [12874257.001]
  • [Cites] J Exp Med. 2003 Jul 21;198(2):249-58 [12874258.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8886-91 [12857946.001]
  • [Cites] J Exp Med. 2003 Sep 1;198(5):737-46 [12939344.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):889-901 [12975455.001]
  • [Cites] Eur J Immunol. 1993 Oct;23(10):2572-7 [8405057.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1579-86 [7520779.001]
  • [Cites] Science. 1995 Nov 10;270(5238):985-8 [7481803.001]
  • [Cites] Immunity. 1995 Nov;3(5):541-7 [7584144.001]
  • [Cites] Nature. 1996 Oct 3;383(6599):443-6 [8837778.001]
  • [Cites] J Biol Chem. 1997 May 30;272(22):14426-33 [9162082.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6216-21 [9177197.001]
  • [Cites] J Exp Med. 1998 Jul 20;188(2):287-96 [9670041.001]
  • [Cites] Int Immunol. 1998 Dec;10(12):1969-80 [9885918.001]
  • [Cites] Nat Med. 2006 Sep;12(9):1088-92 [16921377.001]
  • [Cites] J Immunol. 2006 Oct 1;177(7):4376-83 [16982872.001]
  • [Cites] Immunity. 2006 Nov;25(5):783-93 [17055754.001]
  • [Cites] J Immunol. 2007 Jan 1;178(1):271-9 [17182564.001]
  • [Cites] J Immunol. 2007 Jan 15;178(2):732-9 [17202333.001]
  • [Cites] Immunol Lett. 2007 Feb 15;108(2):183-8 [17270282.001]
  • [Cites] Arthritis Rheum. 2007 Mar;56(3):732-42 [17328044.001]
  • [Cites] Am J Transplant. 2007 Apr;7(4):759-68 [17391121.001]
  • [Cites] Trends Immunol. 2007 Apr;28(4):154-60 [17329168.001]
  • [Cites] Nat Med. 2007 Apr;13(4):423-31 [17384649.001]
  • [Cites] Int Immunol. 2007 Jun;19(6):785-99 [17545278.001]
  • [Cites] J Immunol. 2007 Jul 1;179(1):154-61 [17579033.001]
  • [Cites] J Immunol. 2007 Aug 1;179(3):1427-30 [17641007.001]
  • [Cites] J Leukoc Biol. 2007 Sep;82(3):645-56 [17554014.001]
  • [Cites] Immunology. 2007 Oct;122(2):149-56 [17848162.001]
  • (PMID = 19278420.001).
  • [ISSN] 1365-2567
  • [Journal-full-title] Immunology
  • [ISO-abbreviation] Immunology
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MRC/ G120/854
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Receptors, Tumor Necrosis Factor; 0 / Toll-Like Receptors
  • [Number-of-references] 103
  • [Other-IDs] NLM/ PMC2673359
  •  go-up   go-down


81. Satter EK: Solitary superficial angiomyxoma: an infrequent but distinct soft tissue tumor. J Cutan Pathol; 2009 Oct;36 Suppl 1:56-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary superficial angiomyxoma: an infrequent but distinct soft tissue tumor.
  • Superficial angiomyxoma (SA) is a distinct soft tissue tumor characterized by a circumscribed collection of spindled and stellate fibroblasts that are admixed with thin-walled blood vessels and embedded in a mucinous stroma.
  • Because of its relative infrequent occurrence, the purpose of this article was to present a classical example of an isolated superficial angiomyxoma and discuss the differential diagnosis.
  • [MeSH-major] Back / pathology. Myxoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD / biosynthesis. Antigens, Differentiation, Myelomonocytic / biosynthesis. Diagnosis, Differential. Humans. Immunohistochemistry. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19187115.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human
  •  go-up   go-down


82. Liu F, Zhang L, Hoffman RM, Zhao M: Vessel destruction by tumor-targeting Salmonella typhimurium A1-R is enhanced by high tumor vascularity. Cell Cycle; 2010 Nov 15;9(22):4518-24
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vessel destruction by tumor-targeting Salmonella typhimurium A1-R is enhanced by high tumor vascularity.
  • Our laboratory has previously developed a tumor-targeting double-auxotrophic mutant of Salmonella typhimurium termed A1-R.
  • The present report demonstrates that S. typhimurium A1-R destroys tumor blood vessels and this is enhanced in tumors with high vascularity.
  • Red fluorescent protein (RFP)-expressing Lewis lung cancer cells (LLC-RFP) were transplanted subcutaneously in the ear, back skin, and footpad of nestin-driven green fluorescent protein (ND-GFP) transgenic nude mice, which selectively express GFP in nascent blood vessels.
  • Color-coded in vivo imaging demonstrated that the LLC-RFP ear tumor had the highest cell density and the footpad tumor had the least with the ear tumor having more abundant blood vessels than that on the back or footpad.
  • The tumor-bearing mice were treated with A1-R bacteria via tail-vein injection.
  • Tumors in the ear were the earliest responders to bacterial therapy and hemorrhaged severely the day after A1-R administration.
  • Tumors growing in the back were the second fastest responders to bacterial treatment and appeared necrotic 3 days after A1-R administration.
  • Tumors growing in the footpad had the least vascularity and were the last responders to A1-R.
  • Therefore, tumor vascularity correlated positively with tumor efficacy of A1-R.
  • The present study suggests that bacteria efficacy on tumors involved vessel destruction which depends on the extent of vascularity of the tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene Ther. 1997 Aug;4(8):791-6 [9338007.001]
  • [Cites] Gene Ther. 1996 Feb;3(2):173-8 [8867865.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1408-16 [9537241.001]
  • [Cites] Nat Biotechnol. 1999 Jan;17(1):37-41 [9920266.001]
  • [Cites] Cancer Res. 1955 Aug;15(7):473-8 [13240693.001]
  • [Cites] Cancer Res. 1964 Feb;24:212-6 [14115686.001]
  • [Cites] Cancer Res. 1964 Feb;24:217-21 [14115687.001]
  • [Cites] Cancer Res. 1964 Feb;24:222-33 [14115688.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):755-60 [15644448.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2337-43 [15781648.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5352-7 [15958583.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4208-14 [16618743.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7647-52 [16885365.001]
  • [Cites] Cancer Biol Ther. 2006 Sep;5(9):1120-8 [16855381.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5195-200 [17545599.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10170-4 [17548809.001]
  • [Cites] Cell Prolif. 2009 Feb;42(1):75-82 [19143765.001]
  • [Cites] Cell Cycle. 2009 Mar 15;8(6):870-5 [19221501.001]
  • [Cites] J Cell Biochem. 2009 Apr 15;106(6):992-8 [19199339.001]
  • [Cites] Anticancer Res. 2009 Jun;29(6):1873-8 [19528442.001]
  • [Cites] PLoS One. 2009;4(8):e6692 [19693266.001]
  • [Cites] J Surg Res. 2010 Dec;164(2):248-55 [19766244.001]
  • [Cites] Cancer Gene Ther. 2000 Feb;7(2):269-74 [10770636.001]
  • [Cites] J Clin Invest. 2000 Apr;105(8):1027-30 [10772643.001]
  • [Cites] J Infect Dis. 2000 Jun;181(6):1996-2002 [10837181.001]
  • [Cites] Breast Cancer Res Treat. 2001 Mar;66(2):165-70 [11437103.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15155-60 [11724950.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):142-52 [11773163.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9958-61 [12904579.001]
  • [Cites] Anal Bioanal Chem. 2003 Nov;377(6):964-72 [12879198.001]
  • [Cites] Nat Biotechnol. 2004 Mar;22(3):313-20 [14990953.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13291-5 [15331785.001]
  • [Cites] Gan. 1978 Oct;69(5):613-8 [729960.001]
  • [Cites] Cancer Res. 1980 Jun;40(6):2061-8 [6989495.001]
  • [Cites] Nature. 1981 May 21;291(5812):238-9 [7015147.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4537-44 [9377566.001]
  • (PMID = 21135579.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R43 CA119841; United States / NCI NIH HHS / CA / R44 CA126023; United States / NCI NIH HHS / CA / CA119841; United States / NCI NIH HHS / CA / CA126023; United States / NCI NIH HHS / CA / R43 CA126023
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Intermediate Filament Proteins; 0 / Luminescent Proteins; 0 / Nerve Tissue Proteins; 0 / Nes protein, mouse; 0 / Nestin; 0 / red fluorescent protein; 147336-22-9 / Green Fluorescent Proteins
  • [Other-IDs] NLM/ PMC3048048
  •  go-up   go-down


83. Roodhart JM, Langenberg MH, Daenen LG, Voest EE: Translating preclinical findings of (endothelial) progenitor cell mobilization into the clinic; from bedside to bench and back. Biochim Biophys Acta; 2009 Aug;1796(1):41-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translating preclinical findings of (endothelial) progenitor cell mobilization into the clinic; from bedside to bench and back.
  • It is generally accepted that angiogenesis plays a major role in tumor growth and numerous targeting agents directed against angiogenesis pathways have been developed and approved for clinical use.
  • The recent insight in the mechanism of a systemic host response, in response to various treatment modalities has shed new light on the mechanism of tumor regrowth, early recurrence and metastasis formation during or after treatment.
  • [MeSH-minor] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cell Movement. Cell Proliferation. Drug Delivery Systems. Eukaryotic Initiation Factor-3. Humans. Neoplasm Metastasis. Neovascularization, Pathologic. Research

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19409450.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Biomarkers, Tumor; 0 / EIF3A protein, human; 0 / Eukaryotic Initiation Factor-3
  • [Number-of-references] 93
  •  go-up   go-down


84. Blum A, Back W, Naim R, Hörmann K, Riedel F: Ossifying fibromyxoid tumor of the nasal septum. Auris Nasus Larynx; 2006 Sep;33(3):325-7
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ossifying fibromyxoid tumor of the nasal septum.
  • The fibromyxoid tumor is quite a rare soft tissue tumor and typically presents as an ossifying fibromyxoid tumor (OFMT) in the subcutis of the extremities of adults.
  • We present a case of a fibromyxoid tumor of the nasal septum in a 49-year-old female who complained of nasal airway obstruction and enlargement of the right contour of the nose.
  • Endonasal, endoscopic tumor excision was performed.
  • The tumor contained spindle-shaped and polygonal cells, mucoid pseudocysts and a fibromyxoid stroma with local calcifications.
  • The clinical behaviour of OFMT in general is benign but some reports have documented atypical tumors with histologic signs of malignancy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16600550.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


85. Son SB, Heo YS, Shin WW, Oh TS, Song HJ, Oh CH: A case of cutaneous inflammatory myofibroblastic tumor. Ann Dermatol; 2010 Feb;22(1):91-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of cutaneous inflammatory myofibroblastic tumor.
  • Pseudo-inflammatory tumors are also known as plasma cell granuloma, inflammatory pseudo-tumor and inflammatory myofibroblastic tumor, and these tumors are a group of highly variable proliferations of myofibroblastic cells that are associated with a prominent inflammatory infiltrate.
  • This tumor is known to most commonly occur in the lungs, bladder and gastrointestinal system with only a few cases having been reported in the skin.
  • A previously healthy 26-year-old man presented with a 6-year history of an intermittently pruritic lesion on his back.
  • A diagnosis of inflammatory fibroblastic tumor was made and the nodule was surgically removed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1991 Dec;15(12):1146-56 [1746682.001]
  • [Cites] Pathologica. 2007 Jun;99(3):84-6 [17987729.001]
  • [Cites] Am J Surg Pathol. 1995 Aug;19(8):859-72 [7611533.001]
  • [Cites] Pathology. 1993 Oct;25(4):405-9 [8165009.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2217-29 [8635024.001]
  • [Cites] Histopathology. 1995 Oct;27(4):313-23 [8847061.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1166-72 [9331288.001]
  • [Cites] Semin Diagn Pathol. 1998 May;15(2):102-10 [9606802.001]
  • [Cites] Am J Dermatopathol. 1999 Oct;21(5):449-53 [10535574.001]
  • [Cites] Br J Dermatol. 2001 Jun;144(6):1271-3 [11422062.001]
  • [Cites] Hum Pathol. 2003 Mar;34(3):253-62 [12673560.001]
  • [Cites] J Thorac Surg. 1954 Jul;28(1):55-63 [13175281.001]
  • [Cites] J Cutan Pathol. 2004 Oct;31(9):605-11 [15330992.001]
  • [Cites] Clin Exp Dermatol. 2005 Jul;30(4):369-72 [15953072.001]
  • [Cites] Am J Surg Pathol. 2005 Oct;29(10):1348-55 [16160478.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Jul;20(6):750-1 [16836517.001]
  • [Cites] J Surg Oncol. 2006 Oct 1;94(5):385-91 [16967468.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2007 Mar;21(3):399-401 [17309471.001]
  • [Cites] J Clin Pathol. 2008 Apr;61(4):428-37 [17938159.001]
  • [Cites] Am J Surg Pathol. 1990 Aug;14(8):764-73 [2378396.001]
  • (PMID = 20548893.001).
  • [ISSN] 2005-3894
  • [Journal-full-title] Annals of dermatology
  • [ISO-abbreviation] Ann Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2883410
  • [Keywords] NOTNLM ; Myofibroblastic / Pseudo-inflammatory
  •  go-up   go-down


86. Gromov P, Moreira JM, Gromova I, Celis JE: Proteomic strategies in bladder cancer: From tissue to fluid and back. Proteomics Clin Appl; 2008 Jul;2(7-8):974-88

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic strategies in bladder cancer: From tissue to fluid and back.
  • We have applied protein expression profiling technologies in combination with immunohistochemistry, using fresh tissue and urine samples, to assess bladder cancer heterogeneity and prognosis as well as to generate protein markers for tumor progression and early diagnosis of the disease.
  • In addition, we provide a brief description of a novel and highly promising source of biomarkers, the tumor interstitial fluid (TIF) that perfuses the tumor microenvironment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
  • (PMID = 21136898.001).
  • [ISSN] 1862-8346
  • [Journal-full-title] Proteomics. Clinical applications
  • [ISO-abbreviation] Proteomics Clin Appl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


87. Gillies RJ, Anderson AR, Gatenby RA, Morse DL: The biology underlying molecular imaging in oncology: from genome to anatome and back again. Clin Radiol; 2010 Jul;65(7):517-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The biology underlying molecular imaging in oncology: from genome to anatome and back again.
  • [MeSH-major] Gene Expression Regulation / genetics. Genome / genetics. Molecular Imaging / methods. Neoplasms / genetics. Tumor Microenvironment / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
  • [Cites] J Nucl Med. 1980 Jul;21(7):670-5 [7391842.001]
  • [Cites] Med Phys. 2008 Dec;35(12):5490-500 [19175108.001]
  • [Cites] Radiographics. 1996 Nov;16(6):1413-38; quiz 1462-3 [8946545.001]
  • [Cites] J Comput Assist Tomogr. 1999 Jul-Aug;23(4):615-21 [10433296.001]
  • [Cites] Lancet Oncol. 2005 Mar;6(3):167-75 [15737833.001]
  • [Cites] Biostatistics. 2005 Apr;6(2):293-301 [15772107.001]
  • [Cites] J Nucl Med. 2005 Apr;46(4):675-82 [15809491.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1599-610 [15870830.001]
  • [Cites] Neoplasia. 2005 May;7(5):475-85 [15967100.001]
  • [Cites] Magn Reson Med. 2006 Aug;56(2):235-9 [16929466.001]
  • [Cites] J Magn Reson Imaging. 2006 Sep;24(3):478-88 [16897692.001]
  • [Cites] Diagn Mol Pathol. 2006 Dec;15(4):195-205 [17122647.001]
  • [Cites] Cell. 2006 Dec 1;127(5):905-15 [17129778.001]
  • [Cites] J Neuroimaging. 2007 Apr;17(2):168-74 [17441839.001]
  • [Cites] Pharm Res. 2007 Jun;24(6):1172-85 [17385018.001]
  • [Cites] Nat Biotechnol. 2007 Jun;25(6):675-80 [17515910.001]
  • [Cites] Eur J Cancer. 2007 Jun;43(9):1392-8 [17512190.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3449-59 [17575207.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4104-9 [17827460.001]
  • [Cites] Nat Rev Genet. 2007 Nov;8(11):829-33 [17909537.001]
  • [Cites] Med Phys. 2008 Dec;35(12):5799-820 [19175137.001]
  • [Cites] J Genet Genomics. 2009 Feb;36(2):75-88 [19232306.001]
  • [Cites] Semin Cancer Biol. 2009 Feb;19(1):12-6 [19114105.001]
  • [Cites] Radiother Oncol. 2009 Jun;91(3):393-8 [19328570.001]
  • [Cites] Magn Reson Med. 2009 Aug;62(2):488-99 [19466747.001]
  • [Cites] Nature. 2009 Sep 10;461(7261):193-8 [19741699.001]
  • [Cites] Nat Rev Genet. 2009 Oct;10(10):704-14 [19763153.001]
  • [Cites] Mol Cell. 2009 Sep 24;35(6):741-53 [19782025.001]
  • [Cites] Breast Cancer Res Treat. 2009 Dec;118(3):635-43 [19224362.001]
  • [Cites] NMR Biomed. 2010 Feb;23(2):179-87 [19777501.001]
  • [Cites] J Digit Imaging. 2010 Jun;23(3):342-57 [19172357.001]
  • [Cites] Magn Reson Med. 2007 Nov;58(5):1010-9 [17969122.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5213-8 [18362333.001]
  • [Cites] J Nucl Med. 2008 Jun;49 Suppl 2:24S-42S [18523064.001]
  • [Cites] Curr Opin Cell Biol. 2008 Jun;20(3):274-80 [18468878.001]
  • [Cites] Med Res Rev. 2008 Sep;28(5):645-87 [18271058.001]
  • [Cites] J Magn Reson Imaging. 1999 Dec;10(6):903-7 [10581502.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Neoplasia. 2000 Jan-Apr;2(1-2):152-65 [10933074.001]
  • [Cites] Neoplasia. 1999 Aug;1(3):197-207 [10935474.001]
  • [Cites] Nature. 2001 May 17;411(6835):336-41 [11357140.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):683-93 [12209157.001]
  • [Cites] Technol Cancer Res Treat. 2002 Dec;1(6):419-22 [12625769.001]
  • [Cites] Q J Nucl Med. 2003 Sep;47(3):171-87 [12897709.001]
  • [Cites] Mol Imaging. 2002 Oct;1(4):336-43 [12926229.001]
  • [Cites] Mol Cancer Ther. 2003 Sep;2(9):919-27 [14555711.001]
  • [Cites] J Magn Reson Imaging. 2003 Nov;18(5):530-6 [14579395.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5236-41 [18698042.001]
  • [Cites] Nat Rev Cancer. 2008 Nov;8(11):865-73 [18923434.001]
  • [Cites] Acad Radiol. 2008 Nov;15(11):1437-45 [18995194.001]
  • [Cites] J Nucl Med. 2008 Dec;49(12):1973-9 [18997052.001]
  • [Cites] Biosystems. 2009 Feb;95(2):166-74 [19026711.001]
  • [Cites] J Math Biol. 2009 Apr;58(4-5):579-624 [18839176.001]
  • [Cites] Mol Cell Biol. 1992 Dec;12(12):5447-54 [1448077.001]
  • (PMID = 20541651.001).
  • [ISSN] 1365-229X
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA077575; United States / NCI NIH HHS / CA / U54 CA143970
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS570628; NLM/ PMC4009364
  •  go-up   go-down


88. Klüver N, Herpin A, Braasch I, Driessle J, Schartl M: Regulatory back-up circuit of medaka Wt1 co-orthologs ensures PGC maintenance. Dev Biol; 2009 Jan 1;325(1):179-88
ZFIN. ZFIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulatory back-up circuit of medaka Wt1 co-orthologs ensures PGC maintenance.
  • In mammals, the Wilms' tumor suppressor gene, Wt1, encodes a transcription factor critical for development of the urogenital system.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18992736.001).
  • [ISSN] 1095-564X
  • [Journal-full-title] Developmental biology
  • [ISO-abbreviation] Dev. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligonucleotides, Antisense; 0 / Repressor Proteins; 0 / WT1 Proteins
  •  go-up   go-down


89. Chirgwin JM, Guise TA: Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment. J Cell Biochem; 2007 Dec 15;102(6):1333-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment.
  • Growth of tumor in bone is driven by a vicious cycle: tumor-secreted factors stimulate bone cells, which in turn release growth factors and cytokines.
  • The bone-derived factors fuel the vicious cycle by acting back on the tumor cells.
  • Treatments can inhibit bone cells (osteoclasts and osteoblasts) that are stimulated by tumor-secreted factors.
  • Drugs can also inhibit tumor responses to factors enriched in the bone microenvironment, such as transforming growth factor-beta.
  • Animal models show that these approaches, especially combination treatments, can reduce tumor burden.
  • The results suggest a novel paradigm in which tumor growth can be effectively inhibited by drugs that target cells in the bone microenvironment and not the tumor cells themselves.
  • [MeSH-minor] Forecasting. Humans. Models, Biological. Neoplasm Metastasis / drug therapy. Osteoblasts / physiology. Osteoclasts / physiology. Osteolysis / genetics. Osteolysis / physiopathology. Transforming Growth Factor beta / physiology. Tumor Burden / drug effects

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17907152.001).
  • [ISSN] 0730-2312
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA40035; United States / NCI NIH HHS / CA / CA69158; United States / NIDDK NIH HHS / DK / DK065837
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta
  • [Number-of-references] 52
  •  go-up   go-down


90. Onishi H, Kaya M, Wada T, Nagoya S, Sasaki M, Yamashita T: Giant cell tumor of the sacrum treated with selective arterial embolization. Int J Clin Oncol; 2010 Aug;15(4):416-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the sacrum treated with selective arterial embolization.
  • Giant cell tumor of the sacrum is extremely difficult to manage.
  • In this manuscript, we report an early clinical result of a case of giant cell tumor of the sacrum successfully managed with selective arterial embolization.
  • A 56-year-old woman underwent selective embolization for management of giant cell tumor of the sacrum.
  • We stress the effectiveness of selective arterial embolization as a less invasive and less complicated primary treatment of giant cell tumors of the sacrum.
  • [MeSH-major] Embolization, Therapeutic. Femoral Artery. Giant Cell Tumor of Bone / therapy. Sacrum. Spinal Neoplasms / therapy
  • [MeSH-minor] Activities of Daily Living. Biopsy. Female. Humans. Low Back Pain / etiology. Low Back Pain / prevention & control. Magnetic Resonance Imaging. Middle Aged. Recovery of Function. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20198397.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


91. Haasper C, Länger F, Rosenthal H, Knobloch K, Mössinger E, Krettek C, Bastian L: Coccydynia due to a benign notochordal cell tumor. Spine (Phila Pa 1976); 2007 Jun 15;32(14):E394-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coccydynia due to a benign notochordal cell tumor.
  • OBJECTIVE: To present a rare case of a notochordal cell tumor.
  • SUMMARY OF BACKGROUND DATA: We report on a 27-year-old female patient with pain at the lower back and muscle cramps in the area of the right hip.
  • RESULTS: Histology revealed an intraosseous benign notochordal cell tumor.
  • This tumor represents a recently described notochordal cell proliferation biologically distinct from chordomas.
  • [MeSH-major] Coccyx. Low Back Pain / etiology. Neoplasms, Germ Cell and Embryonal / complications. Spinal Neoplasms / complications
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Notochord / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17572612.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Walvekar RR, Kane SV, D'Cruz AK: Collision tumor of the thyroid: follicular variant of papillary carcinoma and squamous carcinoma. World J Surg Oncol; 2006;4:65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor of the thyroid: follicular variant of papillary carcinoma and squamous carcinoma.
  • BACKGROUND: Collision tumors of the thyroid gland are a rare entity.
  • To the best of our knowledge, this is the first documentation of a collision tumor with a papillary carcinoma and a squamous carcinoma within the thyroid gland.
  • CASE PRESENTATION: A 65 year old woman presented with a large thyroid swelling of 10 years duration and with swellings on the back and scalp which were diagnosed to be a follicular variant of papillary thyroid carcinoma with metastasis.
  • The histopathology revealed a collision tumor with components of both a follicular variant of papillary carcinoma and a squamous carcinoma.
  • Immunohistochemical analysis confirmed the independent origin of these two primary tumors.
  • Adjuvant radio iodine therapy directed toward the follicular derived component of the thyroid tumor and external beam radiotherapy for the squamous component was planned.
  • CONCLUSION: Collision tumors of the thyroid gland pose a diagnostic as well as therapeutic challenge.
  • Metastasis from distant organs and contiguous primary tumors should be excluded.
  • The origins of squamous cancer in the thyroid gland must be established to support the true evolution of a collision tumor and to plan treatment.
  • Treatment for collision tumors depends upon the combination of primary tumors involved and each component of the combination should be treated like an independent primary.
  • The reporting of similar cases with longer follow-up will help define the epidemiology, biology and establish standardized protocols for treatment of these extremely rare tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1997 Nov;174(5):474-6 [9374217.001]
  • [Cites] Eur J Endocrinol. 1997 Sep;137(3):267-9 [9330591.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):574-8 [9028370.001]
  • [Cites] J Surg Oncol. 1988 Nov;39(3):175-8 [3184953.001]
  • [Cites] Head Neck Surg. 1984 Jul-Aug;6(6):1035-42 [6469655.001]
  • [Cites] Endocr Pract. 1999 Mar-Apr;5(2):69-71 [15251691.001]
  • [Cites] Head Neck. 2004 Jul;26(7):637-41 [15229907.001]
  • [Cites] Diagn Cytopathol. 2002 Oct;27(4):227-31 [12357501.001]
  • [Cites] Yonsei Med J. 2002 Jun;43(3):381-4 [12089749.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Apr;128(4):461-2; discussion 463-4 [11926928.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Oct;55(4):543-8 [11678839.001]
  • [Cites] Histopathology. 2001 Sep;39(3):279-86 [11532039.001]
  • [Cites] Arch Pathol Lab Med. 2001 Apr;125(4):541-3 [11260633.001]
  • [Cites] Eur J Surg Oncol. 1999 Dec;25(6):606-9 [10556008.001]
  • [Cites] J Clin Pathol. 2005 Jun;58(6):662-4 [15917423.001]
  • (PMID = 16984659.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1622750
  •  go-up   go-down


93. Poehlein CH, Haley DP, Walker EB, Fox BA: Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts. Eur J Immunol; 2009 Nov;39(11):3121-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts.
  • We reported previously that vaccination of reconstituted, lymphopenic mice resulted in a higher frequency of tumor-specific effector T cells with therapeutic activity than vaccination of normal mice.
  • Here, we show that lymphopenic mice reconstituted with spleen cells from tumor-bearing mice (TBM), a situation that resembles the clinical condition, failed to generate tumor-specific T cells with therapeutic efficacy.
  • However, depletion of CD25(+) Treg from the spleen cells of TBM restored tumor-specific priming and therapeutic efficacy.
  • Adding back TBM CD25(+) Treg to CD25(-) naïve and TBM donor T cells prior to reconstitution confirmed their suppressive role.
  • CD25(+) Treg from TBM prevented priming of tumor-specific T cells since subsequent depletion of CD4(+) T cells did not restore therapeutic efficacy.
  • This effect may not be antigen-specific as three histologically distinct tumors generated CD25(+) Treg that could suppress the T-cell immune response to a melanoma vaccine.
  • Importantly, since ex vivo depletion of CD25(+) Treg from TBM spleen cells prior to reconstitution and vaccination fully restored the generation of therapeutic effector T cells, even in animals with established tumor burden, we have initiated a translational clinical trial of this strategy in patients with metastatic melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Feb 15;101(4):1645-52 [12406877.001]
  • [Cites] J Immunol. 2009 Sep 15;183(6):3682-9 [19692636.001]
  • [Cites] J Immunol. 2000 Oct 1;165(7):3656-62 [11034369.001]
  • [Cites] J Immunol. 2000 Oct 15;165(8):4246-53 [11035058.001]
  • [Cites] J Clin Invest. 2001 Sep;108(6):871-8 [11560956.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):931-6 [11792864.001]
  • [Cites] Immunity. 2002 Feb;16(2):311-23 [11869690.001]
  • [Cites] J Immunol. 2002 May 1;168(9):4272-6 [11970966.001]
  • [Cites] J Immunother. 2002 May-Jun;25(3):207-17 [12000862.001]
  • [Cites] J Clin Invest. 2002 Jul;110(2):185-92 [12122110.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3914-9 [12124318.001]
  • [Cites] J Immunother. 2002 Jul-Aug;25(4):359-72 [12142559.001]
  • [Cites] Science. 2002 Oct 25;298(5594):850-4 [12242449.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):884-90 [12610189.001]
  • [Cites] Cancer Immun. 2002 Feb 22;2:1 [12747746.001]
  • [Cites] Eur J Immunol. 2003 Aug;33(8):2123-32 [12884286.001]
  • [Cites] Transpl Immunol. 2003 Jul-Sep;11(3-4):287-93 [12967782.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10878-83 [12949259.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):6042-50 [14522933.001]
  • [Cites] Biochem Pharmacol. 2003 Dec 1;66(11):2185-91 [14609743.001]
  • [Cites] J Exp Med. 2003 Dec 15;198(12):1875-86 [14676299.001]
  • [Cites] Immunity. 2004 Jan;20(1):107-18 [14738769.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):668-80 [14760090.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5338-45 [15100273.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):771-82 [15381730.001]
  • [Cites] J Immunol. 1991 Jul 15;147(2):729-37 [1830072.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):796-807 [9053507.001]
  • [Cites] Semin Immunol. 1997 Dec;9(6):339-46 [9405262.001]
  • [Cites] Immunogenetics. 1998 Jul;48(2):116-24 [9634475.001]
  • [Cites] J Natl Cancer Inst. 1998 Dec 16;90(24):1894-900 [9862627.001]
  • [Cites] J Immunother. 2005 Jan-Feb;28(1):53-62 [15614045.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2346-57 [15800326.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5211-20 [15958566.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2018-25 [15914560.001]
  • [Cites] J Exp Med. 2005 Oct 3;202(7):907-12 [16203864.001]
  • [Cites] Adv Immunol. 2006;92:187-224 [17145305.001]
  • [Cites] J Immunother. 2007 Jan;30(1):123-9 [17198091.001]
  • [Cites] J Immunother. 2007 Feb-Mar;30(2):240-50 [17471171.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5256-61 [17875753.001]
  • [Cites] J Immunol. 2007 Oct 15;179(8):4969-78 [17911581.001]
  • [Cites] Nature. 2007 Nov 22;450(7169):566-9 [18033300.001]
  • [Cites] Semin Immunol. 2007 Oct;19(5):318-30 [18023361.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):178-87 [18172269.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1032-40 [18281535.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3156-67 [18483384.001]
  • [Cites] Curr Opin Immunol. 2008 Apr;20(2):241-6 [18508251.001]
  • [Cites] Blood. 2008 Aug 1;112(3):610-8 [18519811.001]
  • [Cites] Hum Gene Ther. 2000 Apr 10;11(6):839-50 [10779161.001]
  • (PMID = 19839008.001).
  • [ISSN] 1521-4141
  • [Journal-full-title] European journal of immunology
  • [ISO-abbreviation] Eur. J. Immunol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K22 CA127739-01A1; United States / NCI NIH HHS / CA / R01 CA092254; United States / NCI NIH HHS / CA / R01 CA080964; United States / NCI NIH HHS / CA / 1R01CA92254-01; United States / NCI NIH HHS / CA / K22CA127739; United States / NCI NIH HHS / CA / CA092254-01; United States / NCI NIH HHS / CA / R01 CA092254-01; United States / NCI NIH HHS / CA / R01 CA080964-09; United States / NCI NIH HHS / CA / CA127739-02; United States / NCI NIH HHS / CA / CA127739-01A1; United States / NCI NIH HHS / CA / K22 CA127739; United States / NCI NIH HHS / CA / 1R01CA80964; United States / NCI NIH HHS / CA / K22 CA127739-02; United States / NCI NIH HHS / CA / CA080964-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Interleukin-2 Receptor alpha Subunit
  • [Other-IDs] NLM/ NIHMS180123; NLM/ PMC2850261
  •  go-up   go-down


94. Sikorski CW, Pytel P, Rubin CM, Yamini B: Intradural spinal Wilm's tumor metastasis: case report. Neurosurgery; 2006 Oct;59(4):E942-3; discussion E943
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intradural spinal Wilm's tumor metastasis: case report.
  • OBJECTIVE: Wilm's tumor metastasis to the central nervous system (especially the spine) is rare.
  • We present a case of a lumbosacral intradural drop metastasis in a male child with a remote history of intracerebral Wilm's tumor metastases.
  • CLINICAL PRESENTATION: A 7-year-old boy with known metastatic Wilm's tumor was discovered to have left frontal and parietal metastases.
  • Four years later, he developed low back pain and lower extremity weakness and was found to have an intradural lumbosacral lesion without intracranial recurrence.
  • The tumor was found to be in the subarachnoid space and displaced the nerve roots of the cauda equina to the periphery of the thecal sac.
  • The nerve roots were matted and encased within tumor tissue, thereby limiting the surgery to biopsy only.
  • Unfortunately, follow-up imaging 4 months later revealed little tumor regression, and the patient's neurological condition did not improve significantly.
  • CONCLUSION: Spinal intradural Wilm's tumor metastases are rare.
  • Although the optimal treatment for intra- or extradural Wilm's tumor spine metastases is not known, our patient did not make significant neurological improvement with radiation therapy.
  • [MeSH-major] Dura Mater. Kidney Neoplasms / pathology. Spinal Cord Neoplasms / secondary. Wilms Tumor / secondary

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17038931.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Mandal D, Bhattacharyya A, Lahiry L, Choudhuri T, Sa G, Das T: Failure in peripheral immuno-surveillance due to thymic atrophy: importance of thymocyte maturation and apoptosis in adult tumor-bearer. Life Sci; 2005 Oct 7;77(21):2703-16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Failure in peripheral immuno-surveillance due to thymic atrophy: importance of thymocyte maturation and apoptosis in adult tumor-bearer.
  • Tumor-induced immunosuppression often leads to failure in cancer therapy.
  • Here, in an attempt to understand the course of tumor-dependent immunosuppression in young adult murine model, we found that in Ehrlich's ascites carcinoma (EAC) bearing mice, CD4(+) and CD8(+) populations of peripheral blood were depleted within first week of tumor inoculation.
  • However, there was a rise in these populations at the end of second week only to fall back severely at the end of third week.
  • Interestingly, in thymus, production of CD4(+) and CD8(+) increased during first two weeks of tumor inoculation indicating the effort of thymus to replenish these populations in peripheral blood and spleen in response to their initial depletion, restricting tumor growth in between first and second weeks.
  • Above findings accounted for the significant decrease in CD4(+) and CD8(+) of peripheral blood and spleen by the end of third week culminating in total collapse in the fight back mechanism of host and uncontrolled growth of tumor.
  • All these results signify the importance of thymus in modulating the immune status of the host during tumor development.
  • [MeSH-major] Apoptosis / physiology. Carcinoma, Ehrlich Tumor / immunology. Immunologic Surveillance / physiology. T-Lymphocytes / physiology. Thymus Gland / immunology. Thymus Gland / pathology
  • [MeSH-minor] Animals. Annexin A5 / chemistry. Atrophy. CD4-CD8 Ratio. Cell Cycle. DNA / biosynthesis. DNA / genetics. Flow Cytometry. Fluorescein-5-isothiocyanate. Fluorescent Dyes. Genes, bcl-2. Longitudinal Studies. Mice. Neoplasm Transplantation. Proto-Oncogene Proteins c-bcl-2. Spleen / cytology. Spleen / immunology. bcl-2-Associated X Protein

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019036.001).
  • [ISSN] 0024-3205
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Bax protein, mouse; 0 / Fluorescent Dyes; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; 9007-49-2 / DNA; I223NX31W9 / Fluorescein-5-isothiocyanate
  •  go-up   go-down


96. Kubota K, Furumoto S, Iwata R, Fukuda H, Kawamura K, Ishiwata K: Comparison of 18F-fluoromethylcholine and 2-deoxy-D-glucose in the distribution of tumor and inflammation. Ann Nucl Med; 2006 Oct;20(8):527-33
Hazardous Substances Data Bank. TURPENTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of 18F-fluoromethylcholine and 2-deoxy-D-glucose in the distribution of tumor and inflammation.
  • PURPOSE: The distribution characteristics of 18F-fluoromethylcholine (18F-choline) in tumor and inflammatory tissue were compared with those of 14C or 3H-2-deoxyglucose (2DG) as a substitute for fluorodeoxyglucose (FDG).
  • METHODS: A solid tumor model of AH 109A in the back of Donryu rats and an aseptic inflammation model of turpentine oil injection subcutaneously in rats were used for experiments.
  • Double-tracer high-resolution autoradiographs (ARGs) of tumor and inflammation were obtained using 18F-choline and 14C-2DG.
  • RESULTS: Tumor uptake of 18F-choline reached a peak at 30 min, when the tumor to blood ratio was 5.1.
  • Both tumor and inflammation uptake of 2DG were higher than those of 18F-choline.
  • 18F-choline uptake by inflammation was lower than that by tumor.
  • The tumor to brain uptake ratio was 5.7 with 18F-choline and 1.2 with 2DG.
  • Our results may suggest the feasibility of 18F-choline-PET imaging for the differential diagnosis of cancer and chronic inflammation in lung and brain.
  • [MeSH-minor] Animals. Autoradiography / methods. Brain / pathology. Inflammation / diagnosis. Lung / pathology. Male. Neoplasm Transplantation. Rats. Tissue Distribution. Turpentine / pharmacology

  • Hazardous Substances Data Bank. 2-DEOXY-D-GLUCOSE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17134019.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0 / fluoromethylcholine; 0 / methylcholine; 8006-64-2 / Turpentine; 9G2MP84A8W / Deoxyglucose; N91BDP6H0X / Choline
  •  go-up   go-down


97. Rongioletti F, Baldari M, Carli C, Fiocca R: Squamomelanocytic tumor: a new case of a unique biphenotypic neoplasm of uncertain biological potential. J Cutan Pathol; 2009 Apr;36(4):477-81
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamomelanocytic tumor: a new case of a unique biphenotypic neoplasm of uncertain biological potential.
  • Squamomelanocytic tumor is an uncommon cutaneous neoplasm composed of an admixture of melanocytic and squamous cellular phenotypes.
  • We describe a case of this tumor in a 94-year-old man who presented with a nodule on the back.
  • This tumor represents a proliferation of two phenotypic cells that are distinctive for their intimate admixture and singular immunohistochemical profile.
  • The authors discuss the histogenesis of this tumor, suggesting that it could represent an atypical solid-cystic hidradenoma colonized by a melanocytic malignant component.
  • The biological behavior of this neoplasm remains currently uncertain.
  • [MeSH-minor] Aged, 80 and over. Back / pathology. Humans. Immunohistochemistry. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19278436.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


98. Doita M, Miyamoto H, Nishida K, Nabeshima Y, Yoshiya S, Kurosaka M: Giant-cell tumor of the tendon sheath involving the thoracic spine. J Spinal Disord Tech; 2005 Oct;18(5):445-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant-cell tumor of the tendon sheath involving the thoracic spine.
  • Giant-cell tumor of the tendon sheath is a common benign lesion of the synovial membrane that frequently occurs in the hand.
  • It is related to pigmented villonodular synovitis and the occurrence of pigmented villonodular synovitis or giant-cell tumor of the tendon sheath in the axial skeleton is very rare.
  • To data, only three cases of giant-cell tumor of the tendon sheath involving cervical spine have been reported, compared with 26 cases of pigmented villonodular synovitis.
  • Pigmented villonodular synovitis involving the thoracic spine is also extremely rare and our case represents the first reported case of a giant-cell tumor of the tendon sheath involving the thoracic spine.
  • A 26-year-old man presented with left back pain without neurological deficit.
  • Although giant-cell tumor of the tendon sheath in the thoracic spine may be extremely uncommon, it should be considered in the differential diagnosis, especially when a benign lesion appears to originate in the face joint.
  • [MeSH-major] Giant Cell Tumors / radiography. Giant Cell Tumors / surgery. Soft Tissue Neoplasms / radiography. Soft Tissue Neoplasms / surgery. Tendons. Thoracic Vertebrae

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16189458.001).
  • [ISSN] 1536-0652
  • [Journal-full-title] Journal of spinal disorders & techniques
  • [ISO-abbreviation] J Spinal Disord Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Kaku S, Tanaka T, Ohtuka T, Seki K, Sawauchi S, Numoto RT, Murakami S, Komine K, Abe T: Perisacral gastrointestinal stromal tumor with intracranial metastasis. Case report. Neurol Med Chir (Tokyo); 2006 May;46(5):254-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perisacral gastrointestinal stromal tumor with intracranial metastasis. Case report.
  • A 68-year-old woman presented with an extremely rare intracranial metastasis from a gastrointestinal stromal tumor (GIST) manifesting as left hemiparesis 2 years after resection of a sacral tumor adjacent to the coccygeal bone.
  • Magnetic resonance imaging revealed an intracranial tumor in the right parietal lobe.
  • Craniotomy was performed to completely remove the tumor.
  • Although the tumor was located extra-axially, only internal carotid angiography showed mass staining.
  • Seven months after surgery, the tumor recurred.
  • Repeat craniotomy was performed to remove the recurrent tumor.
  • Immunohistochemical analysis showed that the tumor cells were positive for c-kit and CD34, and the tumors were identified as intracranial metastasis of GIST.
  • Following the second intracranial surgery, the patient developed severe lower back pain caused by metastatic tumor invading the lumbar spine and ureter.
  • To avoid surgical complications and to reduce tumor volume, imatinib mesylate (Gleevec) was administered.
  • The severe pain was relieved, although the tumor was not reduced.
  • In this case, the extra-axial tumor was fed only by the internal carotid artery.
  • [MeSH-major] Brain Neoplasms / secondary. Gastrointestinal Neoplasms / pathology. Gastrointestinal Stromal Tumors / secondary. Sacrum / pathology
  • [MeSH-minor] Aged. Female. Humans. Neoplasm Invasiveness. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16723820.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


100. Yu WL, Lu JM, Ouyang J, Wei YL, Fang M, Wang XW: [Clinical study of open vertebroplasty in treating thoracolumbar metastatic tumor]. Zhongguo Gu Shang; 2010 Oct;23(10):739-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of open vertebroplasty in treating thoracolumbar metastatic tumor].
  • OBJECTIVE: To explore the clinical application and therapeutic effect of open vertebroplasty for thoracolumbar metastatic tumor.
  • METHODS: From September 2003 to December 2009, 21 patients with thoracolumbar metastatic tumor underwent the surgical procedure of posterior spinal cord decompression and open vertebroplasty combined with short-segmental pedicle screw fixation during the same intervention.
  • The primary focus of the tumor of 19 cases were established, lung carcinoma was in 8 cases, breast cancer in 4 cases, prostate carcinoma in 4 cases, hepatocarcinoma in 2 cases and thyroid carcinoma in 1 case.
  • The lumbar-back pain, height of anterior and posterior vertebral body, Cobb angle and spinal function were recorded before and after operation.
  • The VAS score of lumbar-back pain decreased from 8.78 +/- 0.45 preoperatively to 2.25 +/- 0.36 postoperatively.
  • [MeSH-major] Lumbar Vertebrae / pathology. Neoplasm Metastasis / therapy. Spinal Neoplasms / surgery. Thoracic Vertebrae / pathology. Vertebroplasty / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21137282.001).
  • [ISSN] 1003-0034
  • [Journal-full-title] Zhongguo gu shang = China journal of orthopaedics and traumatology
  • [ISO-abbreviation] Zhongguo Gu Shang
  • [Language] chi
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down






Advertisement